fhoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche finance report finance report finance brief key results sales core operating profit margin cer growth sales pharmaceuticals diagnostics group change sales chf chf chf cer ifrs results sales operating profit net income net income attributable roche shareholders diluted eps chf dividend per share chf core results research development core operating profit core eps chf free cash flow operating free cash flow free cash flow change chf chf chf cer net debt capitalisation debt equity proposed board directors cer constant exchange rates percentage changes constant exchange rates calculated using simulations reconsolidating results constant exchange rates average rates year ended december core results core eps earnings per share exclude noncore items global restructuring plans amortisation impairment goodwill intangible assets allows transparent assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core concept fully described pages reconciliations ifrs core results given cover running stringent controls medicines ensure products provided patients meet respective production criteria stefan kamber inprocesscontrol expert roche solids production unit basel conducts one multiple checks cotellic new cancer medicine approved fda european commission november finance brief roche roche group reported strong overall results sales grew constant exchange rates cer core earnings per share increased excluding impact onetime income divestment filgrastim franchise rights underlying core earnings grew sales group sales increased cer chf billion growth chf terms pharmaceuticals sales growth cer due continued strong growth franchise avastin oncology portfolio immunology sales esbriet actemraroactemra increased sales pegasys decreased due competition new generation treatments valcytecymevene xeloda decreased due generic competition diagnostics sales showed growth cer professional diagnostics major contributor operating results core operating profit increased cer chf billion decline chf terms excluding onetime income divestment filgrastim franchise rights underlying core operating profit grew research development expenditure grew cer chf billion core basis focus oncology immunology neuroscience therapeutic areas research development costs group sales ifrs operating results include noncore expenses chf billion major factors chf billion amortisation intangible assets chf billion global restructuring plans notably pharmaceuticals divisions strategic realignment manufacturing network nonoperating results core net financial expenses increased chf billion chf billion driven lower income divestments equity securities ifrs net financial expenses additionally includes loss chf billion major debt restructuring net income ifrs net income increased cer chf billion decline chf terms core earnings per share increased cer chf terms excluding onetime income divestment filgrastim franchise rights underlying earnings per share grew cash flows operating free cash flow chf billion decrease cer chf terms growth operating profit offset higher capital investments lower increase accounts payable free cash flow decreased cer chf terms chf billion driven operating free cash flow decline higher tax dividend payments acquisitions notably majority stake foundation medicine ariosa kapa acquisitions diagnostics sequencing business utilised total chf billion cash financial position net working capital decreased cer due increase payables since end net debt stable chf billion free cash flow largely absorbed acquisitions net debt percentage total assets credit ratings strong moodys standard poors aa shareholder return dividends proposal made increase dividends chf per share represent th consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr representing combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles noncurrent liabilities operating segment information current liabilities net financial expense provisions contingent liabilities income taxes debt business combinations equity attributable roche shareholders global restructuring plans subsidiaries property plant equipment noncontrolling interests goodwill employee benefits intangible assets pensions postemployment benefits inventories equity compensation plans accounts receivable earnings per share nonvoting equity security marketable securities statement cash flows cash cash equivalents risk management noncurrent assets related parties current assets subsidiaries associates accounts payable significant accounting policies report roche management internal control financial reporting report statutory auditor general meeting shareholders roche holding ltd basel report independent auditor internal control financial reporting board directors roche holding ltd basel multiyear overview supplementary information roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings report statutory auditor general meeting shareholders roche holding ltd basel financial review roche group financial review roche group results sales billions chf core operating profit billions chf cer growth sales net income attributable roche shareholders billions chf core eps chf roche groups results showed sales growth core operating profit growth constant exchange rates cer sales increased driven oncology immunology portfolios especially medicines herpositive breast cancer professional diagnostics business core eps grew lower rate sales due base effect onetime income divestment filgrastim franchise rights excluding item core operating profit core eps grew ahead sales operating free cash flow chf billion sales decrease cer due increased capital expenditure investments intangible assets well higher increase net working capital sales pharmaceuticals division rose chf billion increase driven oncology portfolio especially franchise grew avastin sales higher increased use recently launched indications sales immunology grew actemraroactemra xolair increasing respectively strong uptake esbriet following us launch sales pegasys declined due competition new generation treatments sales valcyte cymevene xeloda fell due generic competition tamiflu sales fell due relatively mild influenza season regions showed growth pharmaceuticals sales us significant diagnostics sales grew chf billion securing divisions leading market position major growth area professional diagnostics sales increasing led immunodiagnostics business molecular diagnostics tissue diagnostics increased respectively sales diabetes care decreased due continued challenging market environment us core operating profit increased pharmaceuticals division fell diagnostics division pharmaceuticals division growth underlying business compensated base effect divestment income chf million filgrastim franchise rights excluding item core operating profit pharmaceuticals increased manufacturing costs higher due capacity expansion sourcing strategy biologics together higher inventory writeoffs marketing distribution costs grew due launch rollout new products notably recently acquired product esbriet research development continued investments oncology immunology inflammation respiratory therapeutic areas diagnostics core operating profit lower mainly due higher sales offset costs sequencing business increased research development costs professional diagnostics diabetes care performance impacted price erosion major markets us operating free cash flow chf billion decrease cer chf terms continuous strong operating cash generation offset capital investments manufacturing facilities site development projects notably switzerland us germany increased level inlicensing activities lower increase accounts payable free cash flow chf billion decrease relative mainly driven lower operating free cash flow higher tax payments higher annual dividend payments roche finance report roche group financial review ifrs net income grew cer compared increase core net income addition items described core results ifrs results include base effect impairment goodwill intangible assets year chf billion net tax swiss franc appreciated number currencies particular euro japanese yen latin american european currencies effects partly offset stronger us dollar relative average rate overall impact negative growth rates expressed swiss francs compared constant exchange rates percentage point impact sales percentage point impact core operating profit percentage point impact core eps currency translation sensitivity groups results movements foreign currency exchange rates included income statement change change chf chf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests eps basic chf eps diluted chf core results sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core eps basic chf core eps diluted chf roche finance report financial review roche group sales sales increased cer chf usd chf billion sales pharmaceuticals division rose chf billion driven growth medicines herpositive breast cancer well avastin esbriet mabtherarituxan actemraroactemra avastin sales grew driven increased use recently launched indications immunology strong uptake esbriet following us launch late also subcutaneous formulation actemraroactemra sales xolair increased pharmaceuticals sales increased regions particularly us franchise grew sales pegasys declined due competition new generation treatments valcytecymevene xeloda sales declined products offpatent us xeloda additionally offpatent europe tamiflu sales fell due relatively mild influenza season late compared severe influenza season comparative period sales lucentis declined due strong competition diagnostics division sales chf billion increase cer division retains leading market position major growth area professional diagnostics represents half divisions sales grew led immunodiagnostics business sales molecular diagnostics tissue diagnostics increased respectively diabetes care sales decreased due continuing us reimbursement cuts pricing pressure divisional operating results pharmaceuticals diagnostics corporate group chf chf chf chf sales core operating profit margin sales operating profit margin sales operating free cash flow margin sales divisional operating results development results compared pharmaceuticals diagnostics corporate group sales increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operating free cash flow increase cer margin percentage point increase core operating results pharmaceuticals division divisions core operating profit increased cer line sales increase cost growth contained line increased sales lower royalties operating income driven oneoff income chf million divestment filgrastim franchise rights excluding income divisions core operating profit grew diagnostics division core operating profit cer compared sales increase increased costs recently acquired companies sequencing business offset growth underlying business diabetes care impacted price erosion major markets like us roche finance report roche group financial review acquisitions roche group completed acquisition several companies including previously announced total cost acquired net assets chf billion cash chf billion fair value contingent consideration arrangements april pharmaceuticals division acquired controlling interest foundation medicine fmi usd billion transaction advances fmis marketleading position molecular information genomic analysis providing group unique opportunity optimise identification development novel treatment options cancer patients pharmaceuticals division also completed acquisition trophos diagnostics division acquired geneweave biosciences molecular diagnostics sequencing business ariosa diagnostics signature diagnostics capp medical kapa biosystems september pharmaceuticals division acquired controlling interest intermune usd billion acquisition added new medicine idiopathic pulmonary fibrosis esbriet roche portfolio noncore costs relating intermune included intangible asset amortisation chf billion expense chf million release inventory fair value adjustment group issued usd billion debt finance transaction annual financial statements accounting intermune dutalys bina acquisitions provisional based preliminary information valuations assets liabilities valuations finalised result comparative balance sheet information december restated contingent consideration provisions increased chf million chf billion mainly due new provisions chf million arising acquisitions addition net increase provisions chf million recorded general administration expense mainly due progression lead product candidate seragon acquisition partially offset payments chf million mainly related iquum acquisition details given notes annual financial statements global restructuring plans group continued implementation several major global restructuring plans initiated prior years notably programme diagnostics divisions diabetes care business november pharmaceuticals division announced strategic realignment manufacturing network including exiting four sites total costs chf billion considerably higher costs chf billion due strategic realignment pharmaceuticals divisions manufacturing network costs chf billion global restructuring plans costs incurred millions chf diagnostics site consolidation plans total global restructuring costs employeerelated costs site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs includes diabetes care autonomy speed restructuring plan includes pharmaceuticals division strategic realignment manufacturing network includes plans pharmaceuticals division research development strategic realignment field force reductions europe asiapacific roche finance report financial review roche group diagnostics division september roche diabetes care announced autonomy speed initiative enable business focus diabetes cares specific requirements speed processes decisionmaking drive efficiencies costs chf million incurred mainly consultancy itrelated costs well employeerelated costs spending smaller plans within division chf million included costs related certain projects restructuring former applied science business site consolidation november pharmaceuticals division announced strategic realignment manufacturing network including exiting manufacturing sites clarecastle ireland legans spain segrate italy florence us costs plan expected order chf billion chf billion cash plan expected run approximately positions affected costs plan chf million chf million noncash writedowns accelerated depreciation property plant equipment additional costs recorded pharmaceuticals division outsourcing logistics rosny site france closure manufacturing site toluca mexico divestment plans nutley site track global restructuring plans major items chf million pharmaceuticals division research development strategic realignment chf million various initiatives reduce field force europe asiapacific regions details given note annual financial statements impairment goodwill intangible assets minor impairments pharmaceuticals division impairment charges totalled chf million relating decisions stop development various compounds collaboration project different alliance partners impairments diagnostics division total impairment charges recorded goodwill intangible assets chf billion major part tissue diagnostics business impairment charges chf million goodwill chf million product intangible assets details given notes annual financial statements legal environmental settlements legal environmental settlements include provision chf million remediation costs clarecastle production site ireland following strategic realignment pharmaceuticals divisions manufacturing network significant developments details given note annual financial statements major debt restructuring result attractive financing conditions capital markets group decided september restructure part debt consisted refinancing usd billion notes coupons originally due eur billion notes coupons originally due issuance usd billion notes due coupons major debt restructuring resulted loss chf million details given note annual financial statements treasury taxation core financing costs chf billion decrease mainly due losses debt redemption interest costs lower core financial expenses chf million reflecting net foreign exchange loss chf million mainly arising venezuela argentina partially offset chf million net income equity securities core tax expenses increased chf billion groups effective core tax rate increased compared mainly due higher percentage core profit contribution coming tax jurisdictions higher local tax rates average group tax rate notably us roche finance report roche group financial review net income earnings per share ifrs net income diluted eps decreased chf terms cer ifrs income increased diluted eps increased core net income increased core eps increased cer core basis excludes noncore items global restructuring costs amortisation impairment goodwill intangible assets alliance business combination costs excluding income divestment filgrastim franchise rights chf million related tax effects chf million underlying core eps grew cer net income change change chf chf chf cer ifrs net income reconciling items net tax global restructuring intangible asset amortisation goodwill intangible asset impairment alliances business combinations legal environmental settlements major debt restructuring pension plan settlements normalisation tax benefits equity compensation plans core net income supplementary net income eps information given pages includes calculations core eps reconciles core results groups published ifrs results financial position financial position change change chf chf chf cer pharmaceuticals net working capital longterm net operating assets diagnostics net working capital longterm net operating assets corporate net working capital longterm net operating assets net operating assets net debt pensions income taxes nonoperating assets net total net assets disclosed note annual financial statements balance sheet december restated following finalisation net assets acquired related intermune dutalys bina acquisitions reconciliation previously published balance sheet provided note roche finance report financial review roche group compared start swiss franc appreciated currencies notably euro brazilian real resulted overall negative translation impact balance sheet positions us dollar ended year rate swiss franc beginning year therefore little translation impact balance sheet positions exchange rates used given pharmaceuticals division net working capital decreased cer due increase payables since end due exercise purchase option offices south san francisco addition trade receivables decreased mainly us consequence lower tamiflu sales end good collections inventory levels rose due expansion production capacities including deliveries external manufacturing partners also due higher sales volumes new established products longterm net operating assets increased result goodwill intangible assets foundation medicine trophos acquisitions higher capital expenditure well purchase option exercise offices south san francisco diagnostics increase net working capital result strong sales performance well challenging political economic situations resulted increase inventories account receivables longterm net operating assets increased due intangible assets goodwill various acquisitions net debt stable chf billion free cash flow largely absorbed acquisitions net pension liability decreased chf billion main driver translation eurodenominated unfunded plans germany swiss francs consolidation net tax liabilities increased mainly due deferred tax effects acquisition accounting free cash flow free cash flow change change chf chf chf cer pharmaceuticals diagnostics corporate operating free cash flow treasury activities taxes paid dividends paid free cash flow groups operating free cash flow chf billion decrease cer chf terms operating cash generation absorbed higher investments property plant equipment site infrastructure office development projects expansion manufacturing facilities increased inlicensing arrangements pharmaceuticals division free cash flow chf billion decreased significantly compared due relatively lower operating free cash flow higher tax payments increase annual dividend roche finance report roche group financial review pharmaceuticals division operating results pharmaceuticals division operating results change change chf chf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results core eps sales overview pharmaceuticals division sales therapeutic area change sales sales therapeutic area chf chf cer oncology immunology infectious diseases ophthalmology neuroscience therapeutic areas total sales pharmaceuticals division sales increased cer strong growth oncology immunology products sales growth primarily driven following products herceptin avastin perjeta esbriet mabtherarituxan actemraroactemra kadcyla products together contributed chf billion cer sales growth growth franchise resulted increased demand perjeta herceptin combination therapy continued uptake kadcyla avastin sales grew regions driven increased use recently launched indications mabthera rituxan sales also increased notably us sales immunology increased due demand esbriet following us launch late due growth actemraroactemra regions subcutaneous formulation xolair grew due increasing uptake recently launched indication chronic idiopathic urticaria roche finance report financial review roche group sales pegasys declined due competition new generation treatments sales valcytecymevene xeloda fell due generic competition tamiflu sales lower due relatively mild influenza season late compared severe season late sales lucentis declined due strong competition product sales pharmaceuticals division sales change sales sales chf chf cer oncology avastin herceptin mabtherarituxan perjeta tarceva kadcyla xeloda zelboraf others total oncology immunology actemraroactemra mabtherarituxan xolair cellcept pulmozyme esbriet others total immunology infectious diseases tamiflu pegasys valcytecymevene rocephin others total infectious diseases ophthalmology lucentis total ophthalmology neuroscience madopar others total neuroscience therapeutic areas activasetnkase mircera neorecormonepogin nutropin others total therapeutic areas total sales total mabtherarituxan sales chf million chf million split oncology immunology franchises roche finance report roche group financial review mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukemia cll follicular lymphoma fl rheumatoid arthritis ra well certain types ancaassociated vasculitis mabtherarituxan regional sales change sales sales chf chf cer united states europe japan international total sales sales higher driven primarily strong growth us oncology immunology sales international region grew driven growth eastern europe middle east africa subregion public sector sales latin america sales europe increased mainly due france italy franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin herceptin regional sales change sales sales chf chf cer united states europe japan international total sales perjeta regional sales change sales sales chf chf cer united states europe japan international total sales kadcyla regional sales change sales sales chf chf cer united states europe japan international total sales overall growth franchise herceptin sales grew continued strong growth us resulting longer duration treatment combination perjeta early advanced breast cancer demand international region grew strongly growth subregions europe sales stable perjeta grew regions particularly europe us approved use surgery early stage aggressive breast cancer kadcyla sales doubled europe reimbursement granted italy france spain sales also increased international region japan roche finance report financial review roche group avastin advanced colorectal breast lung kidney cervical ovarian cancer relapsed glioblastoma type brain tumour avastin regional sales change sales sales chf chf cer united states europe japan international total sales demand avastin strong sales growth regions us sales grew driven expanded use recently launched indications cervical ovarian cancer europe sales grew result increasing treatment ovarian colorectal lung cervical cancer international region growth driven mainly phasing deliveries public sector approval new indications japan sales increased due increasing demand use breast lung cancer lucentis wet agerelated macular degeneration amd macular edema following retinal vein occlusion rvo diabetic macular edema dme lucentis regional sales change sales sales chf chf cer united states total sales sales lucentis declined due competition wet amd dme segments february lucentis approved additional indication diabetic retinopathy people dme actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis actemraroactemra regional sales change sales sales chf chf cer united states europe japan international total sales sales increased growth regions notably us europe driven strong demand subcutaneous formulation represented total actemraroactemra sales increased demand early treatment rheumatoid arthritis monotherapy xolair moderate severe persistent allergic asthma chronic idiopathic urticaria ciu xolair regional sales change sales sales chf chf cer united states total sales us sales increased due higher prescriptions asthma well strong uptake new indication chronic idiopathic urticaria approved march roche finance report roche group financial review tarceva advanced nonsmall cell lung nsclc pancreatic cancer tarceva regional sales change sales sales chf chf cer united states europe japan international total sales sales lower declining sales europe us international region due increasing competitive pressure esbriet idiopathic pulmonary fibrosis ipf esbriet regional sales change sales sales chf chf cer united states europe japan international total sales strong uptake esbriet us following approval fda late sales europe driven germany italy pegasys hepatitis b c pegasys regional sales change sales sales chf chf cer united states europe japan international total sales sales decreased across regions due increased competition new generation hepatitis c therapies tamiflu influenza b tamiflu regional sales change sales sales chf chf cer united states europe japan international total sales sales declined mainly relatively mild influenza season last quarter contrasts severe epidemic influenza season us end sales decreased europe mainly due lower governmental sales pandemic stockpiling compared well japan due higher seasonal demand fourth quarter roche finance report financial review roche group pharmaceuticals division sales region change sales sales region chf chf cer united states europe japan international eemea latin america asiapacific regions total sales eastern europe middle east africa united states sales grew led breast cancer franchise leading products oncology medicines mabtherarituxan avastin herceptin sales chf billion chf billion chf billion respectively addition strong demand esbriet xolair growth negatively impacted sharp decline valcytecymevene xeloda offpatent us well lucentis pegasys due increased competition europe sales increased continued strong growth breast cancer franchise good uptake esbriet addition continued sales growth actemraroactemra avastin growth partially offset lower pegasys tarceva sales tamiflu sales also lower mainly due pandemic stockpiling japan sales grew major growth drivers avastin franchise newly launched alecensa alectinib avastin sales grew due increased demand across approved indications particular use breast lung cancer alecensa alkpositive nonsmall cell lung cancer nsclc launched japan september sales chf million sales osteoporosis medicine edirol also increased international sales increased driven latin america subregion growth latin america mainly due franchise oncology products especially avastin mabtherarituxan actemraroactemra sales also increased significantly sales pegasys xeloda declined asiapacific main drivers growth herceptin avastin mabtherarituxan herceptin growth resulted significant activities ensure patient access medicine china total sales e key emerging markets grew strong volume growth brazil driven market access activities new product launches offsetting price decreases pharmaceuticals division sales e leading emerging markets change sales sales country chf chf cer brazil china india mexico russia south korea turkey total sales roche finance report roche group financial review operating results pharmaceuticals division royalties operating income change chf chf cer royalty income income outlicensing agreements income disposal products total ifrs core basis decrease cer due lower income product disposals partly offset higher outlicensing income income fell due comparative period including chf million income sale filgrastim franchise rights back amgen excluding item growth royalty income stable due receipt certain nonrecurring royalties offsetting lower royalties lucentis enbrel increase outlicensing income due upfront milestone payments exclusive licence agreement galenica commercialisation mircera us payment collaboration partner deblocking amendment pharmaceuticals division cost sales change chf chf cer manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets business combinations inventory fair value adjustment total ifrs basis core costs increased cer percentage sales cost sales increased percentage points increase manufacturing cost goods sold period costs resulted mainly biologics manufacturing capacity increases sourcing strategy addition inventory writedowns increased chf million royalty expenses due lower tamiflu sales expenses collaboration profitsharing agreements increased mainly driven higher copromotion expenses due growing sales mabtherarituxan xolair noncore costs include chf million strategic realignment manufacturing network well amortisation intangible assets intermune acquisition release inventory fair value adjustment pharmaceuticals division marketing distribution change chf chf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis core costs increased cer percentage sales fell additional costs incurred market esbriet following us launch late well ensure increased patient access medicines franchise marketing efforts continued support established launch products restructuring costs relate productivity initiatives mainly asia europe well outsourcing logistics rosny site france pharmaceuticals division research development change chf chf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis roche finance report financial review roche group core costs increased cer percentage sales increased oncology franchise remained primary area research development investments advancement cancer immunotherapy treatments activities also increased immunology inflammation respiratory area driven programmes asthma inflammatory bowel disease idiopathic pulmonary fibrosis addition pharmaceuticals division spent chf million inlicensing pipeline compounds technologies capitalised intangible assets global restructuring costs mainly result pharmaceuticals division research development strategic realignment notably transfer oncology discovery penzberg germany zurich switzerland impairment charges chf million resulting decisions stop development four compounds different alliance partners decision stop one collaboration project alliance partner pharmaceuticals division general administration change chf chf cer administration pensions past service costs gains losses disposal property plant equipment business taxes capital taxes general items general administration core basis global restructuring plans impairment goodwill alliances business combinations legal environmental settlements pensions settlement gains losses total ifrs basis core costs decreased cer due base effect onetime double charge us branded prescription drug fee operating profit impact chf million percentage sales costs fell administration costs decreased due lower management costs us alliance business combination costs relate mainly additional contingent consideration provisions recorded respect seragon acquisition see note annual financial statements legal environmental settlements include provision chf million remediation costs clarecastle production site ireland part pharmaceuticals divisions strategic manufacturing realignment noncore costs include impairment goodwill marcadia acquisition following exit cardiovascular metabolic diseases impairments dedicated goodwill related certain previous acquisitions roche pharmaceuticals chugai subdivisional operating results pharmaceuticals subdivisional operating results millions chf roche pharmaceuticals pharmaceuticals chugai division sales external customers within division core operating profit margin sales external customers operating profit margin sales external customers operating free cash flow margin sales pharmaceuticals division total core operating profit operating profit include elimination chf million chf million unrealised intercompany profits roche pharmaceuticals chugai fall exchange rate japanese yen negative impact approximately percentage points chugais sales growth percentage points core operating profit growth expressed swiss francs compared growth rates japanese yen sales external customers chugai increased japanese yen sales roche chugai also significantly higher resulted increase chugai core operating profit increase chugais operating profit margins additional revenues flowed increase operating profit chugais operating free cash flow increased due increased revenues lower trade receivables resulted timing sales improved customer payment terms roche finance report roche group financial review financial position pharmaceuticals division net operating assets movement movement change change transactions cta chf chf chf cer chf chf trade receivables inventories trade payables net trade working capital receivablespayables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets disclosed note annual financial statements balance sheet december restated following finalisation net assets acquired related intermune dutalys bina acquisitions reconciliation previously published balance sheet provided note absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts compared start swiss franc appreciated currencies notably euro brazilian real resulted overall negative translation impact net operating assets us dollar ended year rate swiss franc beginning year therefore little translation impact balance sheet positions exchange rates used given net working capital decrease cer mainly due increase payables since end due exercise purchase option offices south san francisco trade receivables decreased compared end mainly due lower tamiflu sales us end good collections decrease inventories release noncash intermune inventory fair value adjustment offset increase inventory levels expansion production capacities including deliveries external manufacturing partners inventory levels also rose support sales volume increases new established products longterm net operating assets increased mainly due significant additions property plant equipment well goodwill intangible assets resulting acquisitions foundation medicine trophos property plant equipment increased investments continue made site infrastructure office development projects expansion manufacturing facilities particular switzerland us germany property plant equipment increased following exercise purchase option offices south san francisco increase provisions resulted mainly higher contingent consideration provisions seragon acquisition new restructuring provisions strategic realignment manufacturing network roche finance report financial review roche group free cash flow pharmaceuticals division operating free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales detailed breakdown provided pharmaceuticals divisions operating free cash flow decreased chf billion operating profit net operating cash adjustments decreased cer strong operating performance offset higher capital expenditure increased level inlicensing transactions led decline operating free cash flow increase net working capital mainly due lower increase accounts payable roche finance report roche group financial review diagnostics division operating results diagnostics division operating results change change chf chf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results core eps sales diagnostics division continued increase sales growth cer chf billion professional diagnostics sales growth main growth contributor led immunodiagnostics business molecular diagnostics sales increased growth underlying molecular businesses well genome sequencing business sales doubled diabetes care sales decreased due continued challenging market environment notably us growth tissue diagnostics driven advanced staining product portfolio diagnostics division sales business area change sales sales business area chf chf cer professional diagnostics diabetes care molecular diagnostics tissue diagnostics total sales roche finance report financial review roche group professional diagnostics increase sales business area major contributor divisional performance regions growth primarily driven immunodiagnostics business represents divisional sales also supported clinical chemistry coagulation monitoring businesses professional diagnostics business grew regions especially asiapacific due strong sales china growth reported europe middle east africa emea region mainly due immunodiagnostics clinical chemistry businesses professional diagnostics regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales improved version cobas h troponin test launched june use prehospital emergency care settings diabetes care sales decreased mainly due challenging market conditions blood glucose monitoring portfolio major markets like us sales accuchek mobile grew lancing devices sales sales growth outweighed negative impact phaseout older products accuchek advantage accuchek compact well accuchek avivaperforma decreased insulin delivery systems ids business grew driven infusion systems newly launched accuchek insight system sales north america mainly due spillover medicare prices commercial plans us due reimbursement changes canadas largest provinces sales emea region decreased increased sales germany nordics middle east offset lower sales russia algeria sales grew latin america asiapacific regions mainly driven argentina brazil india diabetes care regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales progress made implementation specific initiatives roche diabetes care started goal streamline processes decisionmaking drive efficiencies continuing develop innovative solutions molecular diagnostics sales rose growth underlying molecular businesses major contributions coming virology hpv cervical cancer screening genomics oncology businesses partly offset sales decline blood screening business sales sequencing business driven nipt noninvasive prenatal testing also contributed overall growth regional growth driven emea increased sales coming germany south africa turkey sales grew north america due strong us sales molecular diagnostics regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales roche finance report roche group financial review tissue diagnostics sales rose driven growth advanced staining portfolio companion diagnostics sales grew regionally growth driven north america emea regions growth driven advanced staining portfolio sales asiapacific grew china main market revenues existing external partnerships showed continued growth tissue diagnostics regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales diagnostics division sales region change sales sales region chf chf cer europe middle east africa emea north america asiapacific latin america japan total sales sales growth diagnostics division driven asiapacific emea regions mainly professional diagnostics sales increase asiapacific mainly driven increasing sales china resulting governmental healthcare investments public demand divisions expanding presence wide portfolio emea region divisions largest market sales increased led growth professional diagnostics molecular diagnostics sales latin america region increased driven professional diagnostics diabetes care sales japan remained stable higher sales professional diagnostics compensating lower molecular diagnostics sales diagnostics division sales e leading emerging markets change sales sales country chf chf cer brazil china india mexico russia south korea turkey total sales operating results diagnostics division royalties operating income change chf chf cer royalty income income outlicensing agreements income disposal products total ifrs core basis royalty income increased cer due back royalty payments professional diagnostics roche finance report financial review roche group diagnostics division cost sales change chf chf cer manufacturing cost goods sold period costs royalty expenses cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer primarily due increase period costs driven higher technical service costs startup validation costs additional depreciation thirdparty instruments supporting growth emerging markets cost sales ratio stable global restructuring costs incurred mainly due ongoing autonomy speed project diabetes care initiative harmonise processes systems within diagnostics diagnostics division marketing distribution change chf chf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis core costs increased cer reflecting higher spend professional diagnostics sequencing business particularly marketing support sales force increase spending mainly driven asiapacific emea regions also higher allowances doubtful receivables southern europe core basis marketing distribution costs percentage sales compared global restructuring costs mainly due reorganisation diabetes care business diagnostics division research development change chf chf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer driven increased spending major projects professional diagnostics investments sequencing business percentage sales research development core costs increased comparative period includes chf million intangible asset impairment related tissue diagnostics business area diagnostics division general administration change chf chf cer administration pensions past service costs gains losses disposal property plant equipment business taxes capital taxes general items general administration core basis global restructuring plans impairment goodwill intangible assets alliances business combinations legal environmental settlements pensions settlement gains losses total ifrs basis roche finance report roche group financial review core costs decreased cer administration expenses grew driven organisational structure sequencing business including new acquisitions percentage sales core costs decreased comparative period includes chf million goodwill impairment related tissue diagnostics business area financial position diagnostics division net operating assets movement movement change change transactions cta chf chf chf cer chf chf trade receivables inventories trade payables net trade working capital receivablespayables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets disclosed note annual financial statements balance sheet december restated following finalisation net assets acquired related intermune dutalys bina acquisitions reconciliation previously published balance sheet provided note absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow include cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts compared start swiss franc appreciated currencies notably euro resulted overall negative translation impact net operating assets diagnostics division significant net asset position euros appreciation swiss franc euro major impact us dollar ended year rate swiss franc beginning year therefore little translation impact balance sheet positions exchange rates used given net working capital net trade working capital increased cer inventories increased due higher demand emerging markets notably brazil mexico china trade payables increased result improving payment terms suppliers trade receivables increased due sales growth fewer factoring initiatives southern europe longterm net operating assets increase cer due increase intangible assets goodwill ariosa signature capp medical geneweave kapa biosystems acquisitions various inlicensing arrangements property plant equipment increased due manufacturing site expansions us germany well headquarter developments switzerland provisions increased due contingent consideration provisions arising acquisitions roche finance report financial review roche group free cash flow diagnostics division operating free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales detailed breakdown provided operating free cash flow diagnostics division decreased chf billion cash generation business offset increases net working capital noted comments financial position property plant equipment increased due instrument placements site development germany us switzerland increased investments intangible assets came inlicensing arrangements corporate operating results corporate operating results summary change chf chf cer administration business taxes capital taxes general items general administration costs core basis global restructuring plans legal environmental settlements total costs ifrs basis financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow see pages definition core results core eps general administration costs stable cer change net operating assets mainly due utilisation provisions remediation activities nutley us grenzach germany corporate operating free cash flow showed higher outflow mainly due utilisation provisions roche finance report roche group financial review foreign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth reported cer chf change cer change chf pharmaceuticals division sales core operating profit diagnostics division sales core operating profit group sales core operating profit exchange rates swiss franc december average december average usd eur jpy compared swiss franc stronger currencies particular euro japanese yen latin american european currencies us dollar appreciation partially offsets negative impact sales developments resulted negative growth impact percentage points equivalent chf billion translated swiss francs currency translation loss operating profit growth percentage points mainly driven depreciation euro january swiss national bank snb announced discontinuing minimum exchange rate swiss francs per euro consequence stock markets switzerland fell significantly value swiss franc increased roche group fundamental impact foreseen example group incurs less overall costs switzerland token key markets us europe japan complete value chains meaning costs incurred local currencies swiss francs see also note annual financial statements group uses swiss franc presentation currency annual financial statements therefore weakening foreign currencies swiss franc negative currency translation impact groups consolidated results reported swiss francs sensitivity group sales core operating profit change average foreign currency exchange rates swiss franc shown table currency sensitivities impact change average exchange rate sales core operating profit versus swiss franc chf chf us dollar euro japanese yen currencies groups revenues primarily generated sales products customers revenues mainly received local currency customers home market although certain emerging markets invoicing made major international currencies us dollar euro costs sales marketing also administration costs follow currency pattern sales majority research development activities incurred groups global research facilities therefore costs mainly concentrated us dollars swiss francs euros general administration costs tend incurred mainly central locations us switzerland germany chugais revenues costs denominated japanese yen roche finance report financial review roche group treasury taxation results treasury taxation results change change chf chf chf cer ifrs results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests financial position treasury taxation net debt pensions income taxes financial noncurrent assets derivatives net collateral net interest payable nonoperating assets net total net assets liabilities free cash flow treasury taxation treasury activities taxes paid dividends paid total see pages definition core results core eps financing costs financing costs ifrs basis lower cer mainly due higher losses debt redemption lower interest expenses core financing costs chf million decrease chf million cer compared interest expenses decreased due continued repayment debt despite new debt issued intermune acquisition loss early redemption debt chf million compared chf million net interest cost defined benefit pension plans decreased chf million due lower discount rates partially offset decrease funding status end group restructured part debt resulting loss repurchase chf million full analysis financing costs given note annual financial statements details major debt restructuring repayments redemptions given note roche finance report roche group financial review financial income expense core financial income expense net expense chf million compared net income chf million net income equity securities chf million chf million comparative period net foreign exchange result reflects hedging costs losses unhedged positions net foreign exchange losses period chf million compared net losses chf million period results include loss chf million venezuela chf million argentina full analysis financial income expense given note annual financial statements income taxes groups effective core tax rate increased percentage points mainly due higher percentage core profit contribution coming tax jurisdictions higher local tax rates average group tax rate notably us analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate chf chf chf chf groups effective tax rate core basis global restructuring plans goodwill intangible assets alliances business combinations legal environmental major debt restructuring normalisation tax benefits equity compensation plans groups effective tax rate ifrs basis financial position net debt position remained stable net pension liability decreased due translation eurodenominated obligation groups plans germany net tax liabilities increased mainly due deferred tax effects newly acquired companies interest payable relates mostly bonds notes coupon payment dates march september decline due chf billion coupon payments bonds notes partly offset interest accrued period december group held financial longterm assets market value chf billion consist mostly holdings biotechnology companies acquired context licensing transactions scientific collaborations us dollar ended year rate swiss franc beginning year therefore little translation impact groups us dollardenominated debt translated swiss francs consolidation free cash flow cash outflow treasury activities increased chf billion due lower proceeds sales equity investments partly offset lower interest payments total taxes paid chf billion increase tax payments made relatively low due tax prepayments made end total dividends paid chf billion increase chf billion compared reflecting increase roche group annual dividend roche finance report financial review roche group cash flows net debt operating free cash flow billions chf free cash flow billions chf free cash flow millions chf pharmaceuticals diagnostics corporate group operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid dividends paid free cash flow operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid dividends paid free cash flow operating free cash flow chf billion decrease cer chf terms mainly due higher capital expenditure property plant equipment switzerland us germany higher investments inlicensing arrangements pharmaceuticals division increased net working capital cash outflow treasury activities increased mainly due lower proceeds sales equity investments total taxes paid chf billion increase due timing tax prepayments total dividends paid higher due increase annual roche group dividend free cash flow chf billion lower due lower operating free cash flow higher tax payments increase dividend roche finance report roche group financial review net debt millions chf december cash cash equivalents marketable securities longterm debt shortterm debt net debt beginning period change net debt free cash flow transactions equity instruments business combinations net divestments subsidiaries hedging collateral arrangements currency translation fair value movements change net debt period december cash cash equivalents marketable securities longterm debt shortterm debt net debt end period net debt currency profile millions chf cash marketable securities debt us dollar euro swiss franc japanese yen pound sterling total us dollardenominated debt includes bonds notes denominated euros swiss francs pounds sterling swapped us dollars therefore consolidated results economic characteristics equivalent us dollardenominated bonds notes net debt position group december chf billion increase chf billion december free cash flow chf billion includes annual dividend payment chf billion offset net cash outflow chf billion acquisitions net outflow chf billion hedging collateral arrangements us dollar ended year rate swiss franc beginning year therefore little translation impact groups us dollardenominated debt translated swiss francs consolidation group entered derivative contracts third parties hedge foreign exchange risk arising bonds notes issued currencies us dollar time collateral agreements entered derivative counterparties mitigate counterparty risk cash collateral balance increased chf billion collateral balance relation hedges nonus dollardenominated bonds notes mainly sensitive foreign exchange rate us dollar euro also pound sterling currently collateral balance moves approximately usd million foreign exchange rates move simultaneously issuance redemption repurchase bonds notes see note annual financial statements impact liquid funds impact net debt position roche finance report financial review roche group pensions postemployment benefits postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans chf million chf million plans classified defined benefit plans even groups potential obligation minor relatively remote possibility arising plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources defined benefit plans expenses groups defined benefit plans chf million chf million increase mainly due increase current service cost chf million driven lower discount rates beginning compared beginning based revised actuarial assumptions end expenses groups defined benefit plans expected approximately chf million driven higher discount rates beginning estimates pension expenses include settlement past servicecurtailment effects might arise year funding status balance sheet position chf chf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability overall funding status ifrs basis groups funded defined benefit plans stable compared start year funded status pension funds monitored local pension fund governance bodies well closely reviewed group level unfunded plans mainly groups german affiliates fully reserved pension obligations invested local affiliates operations unfunded liabilities plans decreased chf billion due increase discount rates germany due translation eurodenominated unfunded plans germany swiss francs consolidation full details groups pensions postemployment benefits given note annual financial statements roche finance report roche group financial review roche shares share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billions chf roche ranked number among peer group consisting roche healthcare companies total shareholder return tsr defined share price growth plus dividends measured swiss francs actual exchange rates constant exchange rates cer roche ranked number yearend return roche shares roche nonvoting equity securities combined performance share nonvoting equity security compared weighted average return peer group chf terms cer healthcare sector outperformed key market sectors despite continuing price rising political pressure roche shares performed line peers constant exchange rates global macroeconomic concerns causing major volatility throughout year roche outperformed peers chf terms swiss market index positive news flow towards end phase iii results ocrelizumab multiple sclerosis strong third quarter sales announcement target upgrade peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb glaxosmithkline johnson johnson lilly merck co novartis pfizer roche sanofi takeda total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source datastream data roche peer index rebased january peer index converted swiss francs daily actual exchange rates currency fluctuations influence representation relative performance roche versus peer index roche finance report financial review roche group proposed dividend board directors proposing increase dividend chf per share nonvoting equity security chf approval annual general meeting th consecutive increase dividend dividend proposal approved shareholders dividend payments total shares nonvoting equity securities amount chf billion chf billion resulting payout ratio based core net income based prices yearend dividend yield roche share yield nonvoting equity security information roche securities given pages information per share nonvoting equity security change chf chf chf eps basic eps diluted core eps basic core eps diluted equity attributable roche shareholders per share dividend per share details please refer notes annual financial statements payout ratio calculated dividend per share divided core earnings per share debt early partial redemption usd million notes originally due march redeemed march following exercise earlycall option december redemption due date march gbp million notes redemption due date july usd billion notes notes redeemed following debt restructuring december group resolved exercise option call early redemption usd million notes due march notes repaid march result attractive financing conditions capital markets group decided september restructure part debt debt restructuring includes redemption usd million notes originally due march redemption usd million notes originally due march redemption usd million notes originally due july redemption eur million notes originally due march mostly refinanced issuing usd billion notes due november major debt restructuring resulted loss chf million transactions described note annual financial statements maturity schedule groups bonds notes outstanding december shown table bonds notes nominal amounts december contractual maturity us dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf beyond total total translated december exchange rates proceeds bonds notes eur billion swapped us dollars therefore consolidated results bonds notes economic characteristics equivalent us dollardenominated bonds notes roche finance report roche group financial review group plans meet debt obligations using existing liquid funds well cash generated business operations free cash flow chf billion included cash generated operations well payment interest tax dividends shortterm financing requirements group commercial paper program us issue usd billion unsecured commercial paper notes committed credit lines usd billion available backstop lines commercial paper notes totalling usd billion outstanding december december usd billion longerterm financing group maintains strong longterm investmentgrade credit ratings aa standard poors moodys facilitate efficient access international capital markets information groups debt given note annual financial statements credit ratings roche group december shortterm longterm outlook moodys p stable standard poors aa stable financial risks december group net debt position chf billion chf billion financial assets group managed conservative way objective meet groups financial obligations times asset allocation considerable portion cash marketable securities group currently holds used debt redemptions liquid funds either held cash invested highquality investmentgrade fixed income securities investment horizon meet liquidity requirements cash marketable securities chf total chf total cash cash equivalents money market instruments debt securities equity securities total cash marketable securities credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group rating profile groups chf billion cash fixed income marketable securities remained strong invested aaaa range group signed netting collateral agreements counterparties order mitigate counterparty risk derivative positions group trade receivables chf billion since beginning financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries december trade receivables eur billion chf billion public customers countries decrease compared december eur terms group uses different measures improve collections countries including intense communication customers forfaiting negotiations payment plans charging interest late payments legal actions strict commercial policies place selected hospitals greece italy accounts hospitals spain portugal closely monitored since groups trade receivables balance southern europe decreased eur terms december group trade receivables greece eur million chf million economic situation greece volatile increased credit risk trade receivables group closely monitoring situation taken appropriate steps manage exposure roche finance report financial review roche group liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time addition current liquidity position group strong cash generation ability future cash flows used repay debt instruments coming years roche enjoys strong longterm investmentgrade credit ratings aa standard poors moodys time roche rated highest available shortterm ratings agencies event financing requirements ratings strong credit roche permit efficient access international capital markets including commercial paper market group committed credit lines various financial institutions totalling chf billion chf billion serve backstop line commercial paper program december debt drawn credit lines market risk market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes interest rates foreign exchange rates equity prices group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices groups var remained stable interest rate risk interest rate risk arises movements interest rates could affect group financial result value group equity group may use interest rate derivatives manage interestraterelated exposure financial result information financial risk management financial risks var methodology included note annual financial statements international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since group implemented various minor amendments existing standards interpretations material impact groups overall results financial position group currently assessing potential impacts various new revised standards interpretations mandatory january group yet applied based analysis date group anticipate material impact groups overall results financial position group also assessing new revised standards mandatory notably ifrs financial instruments ifrs revenues contracts customers ifrs leases roche finance report roche group roche group consolidated financial statements roche group consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche group consolidated financial statements roche group roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidated financial statements roche group consolidated statement comprehensive income millions chf year ended december net income recognised income statement comprehensive income remeasurements defined benefit plans items never reclassified income statement availableforsale investments cash flow hedges currency translation foreign operations items may reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholders noncontrolling interests total roche finance report roche group consolidated financial statements roche group roche group consolidated balance sheet millions chf december december december noncurrent assets property plant equipment goodwill intangible assets deferred tax assets defined benefit plan assets noncurrent assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred tax liabilities defined benefit plan liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity disclosed note balance sheet december restated following finalisation valuation net assets acquired related intermune dutalys bina acquisitions reconciliation previously published balance sheet provided note roche finance report roche group roche group consolidated financial statements roche group consolidated statement cash flows millions chf year ended december cash flows operating activities cash generated operations increase decrease net working capital payments made defined benefit plans utilisation provisions disposal products operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets business combinations divestment subsidiaries interest dividends received sales marketable securities purchases marketable securities investing cash flows total cash flows investing activities cash flows financing activities proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt hedging collateral arrangements changes noncontrolling interests equity contribution noncontrolling interests interest paid dividends paid equitysettled equity compensation plans net transactions equity financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december roche finance report roche group consolidated financial statements roche group roche group consolidated statement changes equity millions chf non share retained fair value hedging translation controlling total capital earnings reserves reserves reserves total interests equity year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests december year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity business combinations changes noncontrolling interests equity contribution noncontrolling interests december roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles basis preparation consolidated financial statements hereafter annual financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except items required accounted fair value approved issue board directors january subject approval annual general meeting shareholders march financial statements annual financial statements roche holding ltd company registered switzerland subsidiaries group groups significant accounting policies changes accounting policies disclosed note key accounting judgements estimates assumptions preparation annual financial statements requires management make judgements estimates assumptions affect reported amounts revenues expenses assets liabilities contingent amounts actual outcomes could differ management estimates estimates underlying assumptions reviewed ongoing basis based historical experience various factors revisions estimates recognised period estimate revised following considered key accounting judgements estimates assumptions made believed appropriate based upon currently available information revenue nature groups business many sales transactions simple structure may consist multiple components occurring different times group also party outlicensing agreements involve upfront milestone payments occurring several years may also involve certain future obligations revenue recognised managements judgement significant risks rewards ownership transferred group retain continuing managerial involvement effective control goods sold obligation fulfilled transactions result cash receipts initially recognised deferred income released income subsequent periods basis performance conditions specified agreement may circumstances level sales returns hence revenues reliably measured cases sales recognised right return expires generally upon prescription products patients order estimate management uses publicly available information prescriptions well information provided wholesalers intermediaries december group chf million provisions accruals expected sales returns chargebacks rebates including medicaid us similar rebates countries estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience december group chf million provisions doubtful receivables see note estimates based analyses ageing customer balances specific credit circumstances historical trends groups experience taking also account current economic conditions business combinations group initially recognises fair value identifiable assets acquired liabilities assumed non controlling interest consideration transferred business combination management judgement particularly involved recognition fair value measurement intellectual property inventories contingent liabilities contingent consideration making assessment management considers underlying economic substance items concerned addition contractual terms roche finance report notes roche group consolidated financial statements roche group impairment december group chf million property plant equipment see note chf million goodwill see note chf million intangible assets see note goodwill intangible assets yet available use reviewed annually impairment property plant equipment intangible assets use assessed impairment triggering event provides evidence asset may impaired assess whether impairment exists estimates expected future cash flows used actual outcomes could vary significantly estimates factors changes discount rates planned use buildings machinery equipment closure facilities presence competition technical obsolescence lower anticipated product sales could lead shorter useful lives impairment pensions postemployment benefits group operates number defined benefit plans fair values recognised plan assets liabilities based upon statistical actuarial calculations measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions december present value groups defined benefit obligation chf million see note actuarial assumptions used may differ materially actual results due changes market economic conditions longer shorter life spans participants changes factors assessed differences could impact defined benefit plan assets liabilities recognised balance sheet future periods legal provisions group provides anticipated legal settlement costs probable outflow resources reliably estimated december group chf million legal provisions status significant legal cases disclosed note estimates consider specific circumstances legal case relevant legal advice inherently judgemental due highly complex nature legal cases estimates could change substantially time new facts emerge legal case progresses reliable estimate made provision recorded contingent liabilities disclosed material environmental provisions group provides anticipated environmental remediation costs probable outflow resources reasonably estimated december group chf million environmental provisions see note environmental provisions consist primarily costs fully clean refurbish contaminated sites including landfills treat contain contamination certain sites estimates inherently judgemental due uncertainties related detection previously unknown contamination method extent remediation percentage problematic materials attributable group remediation sites financial capabilities potentially responsible parties estimates could change substantially time new facts emerge environmental remediation progresses contingent consideration provisions group makes provision estimated fair value contingent consideration arrangements arising business combinations december group chf million contingent consideration provisions see note total potential payments contingent consideration arrangements could chf million see note estimated amounts provided expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario discounted net present value estimates could change substantially time new facts emerge scenario develops income taxes december group current income tax net liability chf million deferred tax net asset chf million see note significant estimates required determine current deferred tax assets liabilities estimates based interpretations existing tax laws regulations factors may impact current deferred taxes include changes tax laws regulations rates changing interpretations existing tax laws regulations future levels research development spending changes pretax earnings leases treatment leasing transactions mainly determined whether lease considered operating finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered assessments consolidation group periodically undertakes transactions may involve obtaining control significant influence companies transactions include equity acquisitions asset purchases alliance agreements transactions structured entities cases management makes assessment whether group control significant influence company whether consolidated subsidiary accounted associated company making assessment management considers underlying economic substance transaction addition contractual terms roche finance report roche group notes roche group consolidated financial statements operating segment information group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenues sale licensing products technology third parties residual operating activities divested businesses certain global activities reported corporate include corporate executive committee global group functions communications human resources finance including treasury taxes pension fund management legal safety environmental services sub divisional information roche pharmaceuticals chugai operating segments within pharmaceuticals division also presented divisional information millions chf pharmaceuticals diagnostics corporate group revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total research development research development costs segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets inventory fair value adjustment equity compensation plan expenses roche finance report notes roche group consolidated financial statements roche group pharmaceuticals subdivisional information millions chf roche pharmaceuticals chugai pharmaceuticals division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination income within division total segment results operating profit elimination profit within division operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total research development research development costs elimination costs within division total segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets inventory fair value adjustment equity compensation plan expenses net operating assets millions chf assets liabilities net assets pharmaceuticals diagnostics corporate total operating nonoperating group disclosed note operating assets pharmaceuticals diagnostics divisions nonoperating liabilities group december restated following finalisation valuation net assets acquired related intermune dutalys bina acquisitions reconciliation previously published balance sheet provided note roche finance report roche group notes roche group consolidated financial statements net operating assets pharmaceuticals subdivisional information millions chf assets liabilities net assets roche pharmaceuticals chugai elimination within division pharmaceuticals division disclosed note operating assets roche pharmaceuticals december restated following finalisation valuation net assets acquired related intermune dutalys acquisitions reconciliation previously published balance sheet provided note information geographical area millions chf revenues external customers noncurrent assets royalties property plant goodwill sales operating income equipment intangible assets switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total disclosed note goodwill intangible assets europe north america december restated following finalisation valuation net assets acquired related intermune dutalys bina acquisitions reconciliation previously published balance sheet provided note supplementary unaudited information sales therapeutic areas pharmaceuticals division business areas diagnostics division given financial review sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenue roche finance report notes roche group consolidated financial statements roche group major customers total three us national wholesale distributors represent quarter groups revenues three us national wholesale distributors amerisourcebergen corp chf billion chf billion mckesson corp chf billion chf billion cardinal health inc chf billion chf billion approximately revenues pharmaceuticals operating segment residual diagnostics segment net financial expense financing costs millions chf interest expense amortisation debt discount net gains losses redemption repurchase bonds notes loss major debt restructuring discount unwind net interest cost defined benefit plans total financing costs financial income expense millions chf net gains losses sale equity securities net gains losses equity security derivatives dividend income writedowns impairments equity securities net income equity securities interest income net gains losses sale debt securities net interest income income debt securities net foreign exchange gains losses net gains losses foreign currency derivatives foreign exchange gains losses net financial income expense associates total financial income expense roche finance report roche group notes roche group consolidated financial statements net financial expense millions chf financing costs financial income expense net financial expense financial result treasury management financial result pension management associates net financial expense income taxes income tax expenses millions chf current income taxes deferred taxes total income tax expense since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year year due changes mix groups taxable income changes local tax rates groups average expected tax rate increased main driver increase higher proportion groups profits us relatively higher local tax rate average group rate proportion us profits lowered goodwill impairments significant local tax rate changes main operating areas group compared groups effective tax rate increased main driver increase higher average expected tax rate disclosed partially offset tax benefit intragroup transfer intangible rights goodwill impairments tax deductible groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect nontaxable incomenondeductible expenses equity compensation plans research development tax credits manufacturing deductions us state tax impacts tax unremitted earnings utilisation previously unrecognised tax losses deferred tax intragroup transfers differences groups effective tax rate income tax benefit recorded respect equity compensation plans varies according price underlying equity chf million chf million income tax benefits recorded solely basis ifrs expense multiplied applicable tax rate benefit approximately chf million chf million would recorded roche finance report notes roche group consolidated financial statements roche group tax effects comprehensive income millions chf pretax aftertax pretax aftertax amount tax amount amount tax amount remeasurements defined benefit plans availableforsale investments cash flow hedges currency translation foreign operations comprehensive income income tax assets liabilities millions chf current income taxes assets liabilities net current income tax assets liabilities deferred taxes assets liabilities net deferred tax assets liabilities disclosed note deferred tax liabilities december restated following finalisation valuation net assets acquired related intermune dutalys bina acquisitions reconciliation previously published balance sheet provided note current income taxes movements recognised net assets liabilities millions chf net current income tax asset liability january income taxes paid business combinations charged credited income statement charged credited equity equity compensation plans transactions shareholders currency translation effects movements net current income tax asset liability december roche finance report roche group notes roche group consolidated financial statements deferred taxes movements recognised net assets liabilities millions chf property plant intangible defined temporary equipment assets benefit plans differences total year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december disclosed note net deferred tax assets liabilities december restated following finalisation valuation net assets acquired related intermune dutalys bina acquisitions reconciliation previously published balance sheet provided note deferred tax net assets temporary differences mainly relate accrued liabilities provisions unrealised profit inventory deferred tax assets recognised tax losses carried forward extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows unrecognised tax losses expiry amount applicable amount applicable chf tax rate chf tax rate within one year one five years five years total unrecognised tax losses five years category includes losses used us state income tax purposes states permit tax reporting separate entity basis deferred tax liabilities established withholding tax taxes would payable remittance earnings foreign subsidiaries amounts currently regarded permanently reinvested total unremitted earnings group regarded permanently reinvested chf billion december chf billion roche finance report notes roche group consolidated financial statements roche group business combinations acquisitions acquisitions net assets acquired millions chf pharmaceuticals diagnostics total intangible assets product intangibles use product intangibles available use marketing intangibles use cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets noncontrolling interests fair value previously held equity interest goodwill total consideration cash contingent consideration total consideration pharmaceuticals trophos march group acquired controlling interest trophos privately owned company based marseille france trophos proprietary screening platform generated olesoxime tro developed spinal muscular atrophy sma rare debilitating genetic neuromuscular disease commonly diagnosed children trophos reported pharmaceuticals division total consideration eur million eur million paid cash eur million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero eur million foundation medicine inc april group acquired controlling interest foundation medicine inc fmi publicly owned us company based cambridge massachusetts fmi listed nasdaq stock code fmi transaction advances fmis marketleading position molecular information genomic analysis providing group unique opportunity optimise identification development novel treatment options cancer patients transaction included broad research development collaboration agreement commercial collaboration agreement aimed expanding global sales efforts fmis current future products fmi reported pharmaceuticals division total cash consideration usd billion roche finance report roche group notes roche group consolidated financial statements identifiable assets acquired liabilities assumed set table pharmaceuticals acquisitions net assets acquired millions chf trophos fmi total intangible assets product intangibles use product intangibles available use cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets noncontrolling interests fair value previously held equity interest goodwill allocated foundation medicine goodwill allocated roche pharmaceuticals total consideration cash contingent consideration total consideration fair value intangible assets determined using excess earning method based management forecasts observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate trophos fmi valuations performed independent valuers fmi accounts receivable comprised gross contractual amounts due chf million expected collectable date acquisition trophos goodwill represents control premium acquired work force synergies expected integrating acquired company groups existing business none goodwill expected deductible income tax purposes fmi goodwill represents strategic value roche pharmaceuticals accessing fmis molecular information genomic analysis also represents premium paid traded market price obtain control business acquired workforce expected synergies none goodwill expected deductible income tax purposes noncontrolling interests fmi measured date acquisition proportionate share fmis identifiable net assets group recognised financial gain chf million fair valuing equity interest fmi held group prior transaction gain included financial income expense directly attributable transaction costs chf million reported pharmaceuticals operating segment within general administration expenses mainly relate fmi acquisition impact trophos fmi acquisitions results pharmaceuticals division group material diagnostics ariosa diagnostics inc january group acquired controlling interest ariosa diagnostics inc ariosa us privately owned company based san jose california ariosa molecular diagnostics testing service provider provides highly targeted accurate noninvasive prenatal testing nipt service clia laboratory using cellfree dna cfdna technology ariosas proprietary harmony prenatal test blood test performed early ten weeks pregnancy ariosa reported diagnostics operating segment part sequencing business total consideration usd million usd million paid cash usd million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero usd million roche finance report notes roche group consolidated financial statements roche group signature diagnostics ag february group acquired controlling interest signature diagnostics ag signature privately owned company based potsdam germany signature translational oncology genomics company develops large blood plasma tissue biobanks multiple cancers including colorectal cancer lung cancer constructed multicentre prospective clinical studies signature reported diagnostics operating segment part sequencing business total cash consideration eur million capp medical inc april group acquired controlling interest capp medical inc capp us privately owned company based palo alto california capp developing technology cancer screening monitoring detection circulating tumour dna ctdna blood capp reported diagnostics operating segment part sequencing business total consideration usd million usd million paid cash usd million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero usd million geneweave biosciences inc august group acquired controlling interest geneweave biosciences inc geneweave us privately owned company based los gatos california geneweave focuses advancing clinical microbiology diagnostic solutions supporting healthcare providers fight drugresistant bacteria geneweaves solutions aid impactful surveillance programmes early therapy guidance successful antibiotic stewardship geneweave reported diagnostics operating segment part molecular diagnostics business total consideration usd million usd million paid cash usd million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero usd million kapa biosystems inc november group acquired controlling interest kapa biosystems inc kapa us privately owned company based wilmington massachusetts kapa rd manufacturing operations cape town south africa kapa core protein engineering technologies enable enzymes tailored suit specific applications sample preparation nextgeneration dna rna sequencing dna amplification molecular diagnostics kapa reported diagnostics operating segment part sequencing business total cash consideration usd million identifiable assets acquired liabilities assumed set table amounts geneweave kapa provisional based preliminary information valuations assets liabilities subject adjustment diagnostics acquisitions net assets acquired millions chf ariosa signature capp geneweave kapa total intangible assets product intangibles use product intangibles available use marketing intangibles use cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration cash contingent consideration total consideration fair value intangible assets determined using excess earning method based management forecasts observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate ariosa capp geneweave kapa valuations ariosa capp geneweave kapa performed independent valuers ariosa kapa accounts receivable comprised gross contractual amounts due chf million chf million respectively expected collectable date acquisition goodwill represents control premium acquired work force synergies expected integrating acquired companies groups existing business none goodwill expected deductible income tax purposes roche finance report roche group notes roche group consolidated financial statements directly attributable transaction costs chf million reported diagnostics operating segment within general administration expenses impact ariosa signature capp geneweave kapa acquisitions results diagnostics division group material acquisitions acquisitions net assets acquired millions chf pharmaceuticals diagnostics total intangible assets product intangibles use product intangibles available use technology intangibles use deferred tax assets inventories accounts receivable marketable securities cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration cash deferred consideration contingent consideration settlement preexisting relationship total consideration disclosed net assets acquired restated following finalisation valuation intermune dutalys bina acquisitions pharmaceuticals seragon pharmaceuticals inc august group acquired controlling interest seragon pharmaceuticals inc seragon us private company based san diego california seragon reported pharmaceuticals division total consideration usd million usd million paid cash usd million deferred cash consideration paid february usd million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero usd billion santaris pharma september group acquired controlling interest santaris pharma santaris private company based near copenhagen denmark santaris reported pharmaceuticals division total consideration usd million usd million paid cash usd million arose contingent consideration arrangement usd million arose settlement preexisting relationship contingent payments based achievement performancerelated milestones range undiscounted outcomes zero usd million intermune inc september group acquired controlling interest intermune inc intermune publicly owned us company based brisbane california listed nasdaq acquisition added new medicine idiopathic pulmonary fibrosis esbriet groups portfolio esbriet approved fda october intermune reported pharmaceuticals division total consideration usd billion paid cash september group issued usd billion aggregate principal amount senior notes part finance transaction roche finance report notes roche group consolidated financial statements roche group dutalys gmbh december group acquired controlling interest dutalys gmbh dutalys private company based vienna austria dutalys reported pharmaceuticals division total consideration usd million usd million paid cash usd million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero usd million identifiable assets acquired liabilities assumed set table pharmaceuticals acquisitions net assets acquired millions chf seragon santaris intermune dutalys total intangible assets product intangibles use product intangibles available use technology intangibles use deferred tax assets inventories accounts receivable marketable securities cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration cash deferred consideration contingent consideration settlement preexisting relationship total consideration disclosed net assets acquired restated following finalisation valuation intermune dutalys acquisitions fair value intangible assets determined using excess earning method based management forecasts observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate seragon santaris intermune dutalys valuations performed independent valuers fair value intermune inventories determined based estimated selling price ordinary course business less estimated costs completion sale reasonable profit margin based effort complete sell inventories intermune accounts receivable comprised gross contractual amounts due chf million goodwill represents control premium acquired work force synergies expected integrating acquired companies groups existing business intermune control premium represents premium paid traded market price obtain control business none goodwill expected deductible income tax purposes directly attributable transaction costs chf million reported pharmaceuticals operating segment within general administration expenses mainly related intermune acquisition three months december intermune contributed revenue chf million net loss chf million results reported pharmaceuticals division group impact seragon santaris dutalys acquisitions results material roche finance report roche group notes roche group consolidated financial statements diagnostics genia technologies inc june group acquired controlling interest genia technologies inc genia us private company based california genia reported diagnostics operating segment part sequencing business total consideration usd million usd million paid cash usd million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones may arise june range undiscounted outcomes zero usd million iquum inc june group acquired controlling interest iquum inc iquum us private company based massachusetts iquum reported diagnostics operating segment part molecular diagnostics business total consideration usd million usd million paid cash usd million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones may arise first half range undiscounted outcomes zero usd million addition group acquired controlling interest related intellectual property holding company cash consideration usd million bina technologies inc december group acquired controlling interest bina technologies inc bina us private company based redwood city california bina reported diagnostics operating segment part sequencing business total consideration usd million usd million paid cash usd million deferred cash consideration paid period date control end usd million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero usd million identifiable assets acquired liabilities assumed set table diagnostics acquisitions net assets acquired millions chf genia iquum bina total intangible assets product intangibles use product intangibles available use deferred tax assets inventories cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration cash deferred consideration contingent consideration total consideration disclosed net assets acquired restated following finalisation valuation bina acquisition fair value intangible assets determined using excess earning method based management forecasts observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate genia iquum fair value intangible asset bina determined using replacement cost method valuations performed independent valuers goodwill represents control premium acquired work force synergies expected integrating acquired companies groups existing business none goodwill expected deductible income tax purposes directly attributable transaction costs chf million reported diagnostics operating segment within general administration expenses impact genia iquum bina acquisitions results reported diagnostics division group material roche finance report notes roche group consolidated financial statements roche group cash flows business combinations acquisitions net cash outflow millions chf pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration paid deferred consideration paid contingent consideration paid cash acquired company transaction costs total net cash outflow restated balance sheet december annual financial statements accounting intermune september dutalys december bina december acquisitions provisional based preliminary information valuations assets liabilities valuations finalised result comparative balance sheet information december restated reconciliation balance sheet net assets acquired published previously using provisional acquisition accounting restated amounts reported comparatives using final acquisition accounting required ifrs business combinations presented restated roche group consolidated balance sheet selected items millions chf december originally measurement published adjustment restated goodwill intangible assets deferred tax liabilities net liabilities net assets measurement adjustments table closing exchange rate december restated pharmaceuticals acquisitions net assets acquired selected items millions chf intermune dutalys originally measurement originally measurement published adjustment restated published adjustment restated intangible assets deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration restated diagnostics acquisition net assets acquired selected items millions chf bina originally measurement published adjustment restated intangible assets deferred tax liabilities net assets liabilities net identifiable assets goodwill total consideration measurement adjustments tables exchange rate date control acquisition annual financial statements acquisition accounting seragon santaris acquisitions also provisional final changes amounts recorded december roche finance report roche group notes roche group consolidated financial statements global restructuring plans group continued implementation several major global restructuring plans initiated prior years notably programme diagnostics divisions diabetes care business november pharmaceuticals division announced strategic realignment manufacturing network including exiting four sites total costs chf billion considerably higher costs chf billion due strategic realignment pharmaceuticals divisions manufacturing network costs chf billion global restructuring plans costs incurred millions chf diagnostics site consolidation plans total year ended december global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs year ended december global restructuring costs employeerelated costs site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs includes diabetes care autonomy speed restructuring plan includes pharmaceuticals division strategic realignment manufacturing network includes plans pharmaceuticals division research development strategic realignment field force reductions europe asiapacific diagnostics division september roche diabetes care announced autonomy speed initiative enable business focus diabetes care specific requirements speed processes decisionmaking drive efficiencies total costs chf million incurred mainly consultancy itrelated costs well employeerelated costs spending smaller plans within division chf million included costs related certain projects restructuring former applied science business roche finance report notes roche group consolidated financial statements roche group site consolidation november pharmaceuticals division announced strategic realignment manufacturing network including exiting manufacturing sites clarecastle ireland legans spain segrate italy florence us costs plan expected order chf billion chf billion cash plan expected run approximately positions affected costs plan chf million chf million noncash writedowns accelerated depreciation property plant equipment additional costs recorded pharmaceuticals division outsourcing logistics rosny site france closure manufacturing site toluca mexico divestment plans nutley site track global restructuring plans total costs chf million major items chf million pharmaceuticals division research development strategic realignment chf million various initiatives reduce field force europe asiapacific regions part realignment april group sold wholly owned subsidiary marcadia biotech inc third party loss disposal chf million see note remaining minor plans totalled chf million total costs chf million major item goodwill impairment chf million related marcadia biotech inc acquisition significant costs included chf million relating european field force reductions pharmaceuticals divisions specialty care unit intermune integration costs chf million costs chf million implementation global outsourcing clinical trial monitoring pharmaceuticals division remaining minor plans totalled chf million global restructuring plans summary costs incurred millions chf employeerelated costs termination costs defined benefit plans employeerelated costs total employeerelated costs site closure costs impairment property plant equipment accelerated depreciation property plant equipment gains losses disposal property plant equipment site closure costs total site closure costs loss divestment subsidiary total costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs roche finance report roche group notes roche group consolidated financial statements global restructuring plans classification costs millions chf depreciation depreciation amortisation amortisation impairment costs total impairment costs total cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics general administration pharmaceuticals diagnostics corporate total total operating segment roche pharmaceuticals chugai diagnostics corporate total roche finance report notes roche group consolidated financial statements roche group property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery construction land improvements equipment progress total january cost accumulated depreciation impairment net book value year ended december january business combinations additions disposals transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january business combinations additions disposals transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value classification impairment property plant equipment millions chf cost sales marketing distribution research development general administration total impairment charge reimbursements received insurance companies respect impairments property plant equipment none borrowing costs capitalised property plant equipment none roche finance report roche group notes roche group consolidated financial statements genentech property purchase option exercise genentech entered master lease agreement mla slough ssf llc slough subsequently acquired health care properties lease property adjacent genentechs south san francisco site developed slough development included total eight buildings construction completed time genentech fully occupied property property lease extension options november genentech exercised purchase option contained mla acquire eight buildings land closing payments made november july total usd million december group recorded addition land buildings land improvements corresponding shortterm longterm liabilities cash outflows group also reclassified finance lease accounting balances previously applied buildings leasing arrangements group lessee finance leases december capitalised cost property plant equipment finance leases chf million chf million net book value assets chf million chf million carrying value leasing obligation chf million chf million reported part debt see note finance leases future minimum lease payments noncancellable leases millions chf future minimum lease present value minimum lease payments payments within one year one five years five years total future finance charges total future minimum lease payments undiscounted operating leases group companies party number operating leases mainly plant machinery including motor vehicles certain shortterm property rentals arrangements impose significant restrictions group total operating lease rental expense chf million chf million operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments roche finance report notes roche group consolidated financial statements roche group leasing arrangements group lessor finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method finance leases future minimum lease receipts noncancellable leases millions chf present value minimum gross investment lease lease receipts within one year one five years five years total unearned finance income na na unguaranteed residual value na na net investment lease accumulated allowance uncollectible minimum lease payments chf million chf million contingent rents recognised income operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements assets reported within property plant equipment lease income operating leases recognised lease term straightline basis december machinery equipment original cost chf billion chf billion net book value chf billion chf billion leased third parties contingent rents recognised income operating leases future minimum lease receipts noncancellable leases millions chf within one year one five years five years total minimum receipts capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling chf billion chf billion roche finance report roche group notes roche group consolidated financial statements goodwill goodwill movements carrying value assets millions chf january cost accumulated impairment net book value year ended december january business combinations impairment charge currency translation effects december cost accumulated impairment net book value allocated following cashgenerating units roche pharmaceuticals foundation medicine chugai total pharmaceuticals division diabetes care professional diagnostics molecular diagnostics tissue diagnostics sequencing strategic goodwill held divisional level total diagnostics division disclosed note goodwill december restated following finalisation valuation net assets acquired related intermune dutalys bina acquisitions reconciliation previously published goodwill provided note impairment charge impairments goodwill impairment charge impairment charges totalling chf million recorded related goodwill impairment charge chf million recorded full writeoff goodwill tissue diagnostics business area within diagnostics division factors leading impairment decrease forecasted cash flows following reassessment latestage future product development returned predesign phase combined additional us reductions immunohistochemistry testing reimbursement laboratories business plan projection period reduced ten years five years ii increase pretax discount rate used impairment testing addition impairments chf million recorded product intangibles tissue diagnostics business see note goodwill impairment charge chf million recorded pharmaceuticals division full writeoff goodwill marcadia biotech inc acquisition memory acquisition arius piramed acquisitions deemed disposed roche finance report notes roche group consolidated financial statements roche group impairment testing pharmaceuticals division divisions operating segments cashgenerating units used testing goodwill part goodwill arising foundation medicine acquisition recorded monitored roche pharmaceuticals level relates strategic development roche pharmaceuticals therefore cashgenerating unit strategic goodwill roche pharmaceuticals recoverable amount used impairment testing higher value use fair value less costs disposal assessing value use cash flow projections based recent business plans approved management business plans include managements latest estimates sales volume pricing well production operating costs assume significant changes organisation chugai foundation medicine fair value less costs disposal determined reference publicly quoted share prices chugai foundation medicine shares business plans projected five years valuations include terminal value beyond years assuming growth discount rate used based aftertax rate derived capital asset pricing model using data capital markets including government twentyyear bonds weighted average tax rate used calculations corresponding pretax discount rate diagnostics division divisions business areas cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition part goodwill ventana acquisition recorded monitored divisional level relates strategic development whole division meaningfully allocated divisions business areas therefore cashgenerating unit goodwill entire division recoverable amount used impairment testing based value use cash flow projections based recent business plans approved management business plans include managements latest estimates sales volume pricing well production operating costs assume significant changes organisation business plans projected five years except sequencing business projected ten years reflecting longterm nature business valuations include terminal value beyond years assuming growth discount rate used based aftertax rate derived capital asset pricing model using data capital markets including government twentyyear bonds weighted average tax rate used calculations corresponding pretax discount rate sensitivity analysis management performed sensitivity analyses roche pharmaceuticals diagnostics division increased discount rate combined decreasing forecast cash flows chugai foundation medicine decreased publicly quoted share prices except molecular diagnostics results sensitivity analyses demonstrated changes key assumptions would cause carrying value goodwill exceed recoverable amount december key assumption changes would result goodwill impairment chf million molecular diagnostics december roche finance report roche group notes roche group consolidated financial statements intangible assets intangible assets movements carrying value assets millions chf product product intangibles marketing technology intangibles available intangibles intangibles use use use use total january cost accumulated amortisation impairment net book value year ended december january business combinations additions transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals chugai diagnostics total group year ended december january business combinations additions divestment subsidiary transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment roche pharmaceuticals chugai diagnostics total group disclosed note intangible assets december restated following finalisation valuation net assets acquired related dutalys bina acquisitions reconciliation previously published intangible assets provided note roche finance report notes roche group consolidated financial statements roche group significant intangible assets december millions chf remaining operating segment net book value amortisation period product intangibles use intermune acquisition roche pharmaceuticals years foundation medicine acquisition roche pharmaceuticals years tanox acquisition roche pharmaceuticals years ariosa acquisition diagnostics years kapa acquisition diagnostics years corangeboehringer mannheim acquisition diagnostics years iquum acquisition diagnostics years product intangibles available use seragon acquisition roche pharmaceuticals na trophos acquisition roche pharmaceuticals na geneweave acquisition diagnostics na cmi acquisition diagnostics na genia acquisition diagnostics na technology intangibles use dutalys acquisition roche pharmaceuticals years santaris acquisition roche pharmaceuticals years classification intangible asset amortisation impairment expenses millions chf amortisation impairment cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics total internally generated intangible assets group currently internally generated intangible assets development criteria recognition asset met intangible assets indefinite useful lives group currently intangible assets indefinite useful lives intangible assets available use mostly represent inprocess research development assets acquired either inlicensing arrangements business combinations separate purchases december approximately projects pharmaceuticals division known decision points within next twelve months certain circumstances could lead impairment due inherent uncertainties research development processes intangible assets available use particularly risk impairment project expected result commercialised product roche finance report roche group notes roche group consolidated financial statements intangible asset impairment impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment impairment charges pharmaceuticals division impairment charges totalling chf million recorded related decisions stop development four compounds different alliance partners chf million assets concerned yet amortised fully written decision stop one collaboration project alliance partner chf million asset concerned amortised fully written impairment charges pharmaceuticals division impairment charges totalling chf million recorded related clinical data assessment one development project chf million asset concerned yet amortised fully written decision stop development compound acquired part previous business combination chf million asset concerned yet amortised fully written decision stop development compound alliance partner chf million asset concerned yet amortised fully written reassessment two projects within hepatitis c virus hcv franchise chf million mainly due negative outcome arbitration competitor assets concerned yet amortised fully written decision stop development one compound chf million asset concerned yet amortised fully written decision stop one collaboration project alliance partner chf million asset concerned yet amortised fully written diagnostics division impairment charges totalling chf million recorded related tissue diagnostics product intangibles available use chf million factors leading impairment reassessment latestage future product development returned predesign phase demonstrate feasibility quality improvement asset concerned yet use fully written tissue diagnostics product intangibles use chf million factors leading impairment decrease forecasted cash flows following us reductions immunohistochemistry testing reimbursement laboratories increase asset specific pretax discount rate used impairment testing assets concerned amortised written estimated recoverable value chf million diabetes care technology intangibles use chf million factors leading impairment decrease forecasted cash flows following change timelines future product development increase assetspecific pretax discount rate used impairment testing assets concerned amortised written estimated recoverable value chf million potential commitments alliance collaborations purchase agreements group party inlicensing similar arrangements alliance partners intangible asset purchase agreements thirdparties arrangements purchase agreements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration purchase agreements groups current estimate future thirdparty commitments payments set table figures undiscounted riskadjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group may arise roche chugai businesses roche finance report notes roche group consolidated financial statements roche group potential future thirdparty collaboration purchase payments december millions chf pharmaceuticals diagnostics group within one year one two years two three years total inventories inventories millions chf raw materials supplies work process intermediates finished goods provision slowmoving obsolete inventory total inventories inventories expensed cost sales totalled chf billion chf billion inventory writedowns year resulted expense chf million chf million accounts receivable accounts receivable millions chf trade receivables notes receivable receivables allowances doubtful accounts chargebacks allowances total accounts receivable allowances doubtful accounts movements recognised liability millions chf january additional allowances created unused amounts reversed utilised year currency translation effects december bad debt expense marketing distribution totalled chf million expense chf million roche finance report roche group notes roche group consolidated financial statements marketable securities marketable securities millions chf availableforsale financial assets equity securities debt securities money market instruments time accounts three months investments total marketable securities marketable securities held fund management purposes primarily denominated swiss francs us dollars euros money market instruments contracted mature within one year december debt securities contracted maturity millions chf within one year one five years five years total debt securities cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents roche finance report notes roche group consolidated financial statements roche group noncurrent assets noncurrent assets millions chf availableforsale investments held fair value availableforsale investments held cost loans receivable longterm trade receivables restricted cash receivables total financial noncurrent assets longterm employee benefits assets total nonfinancial noncurrent assets associates total noncurrent assets availableforsale investments mainly equity investments private biotechnology companies kept part groups strategic alliance efforts unquoted equity investments classified availableforsale measured cost fair value measured reliably current assets current assets millions chf accrued interest income derivative financial instruments restricted cash receivables total financial current assets prepaid expenses taxes recoverable assets total nonfinancial current assets total current assets receivables mainly related royalty licensing income receivables roche finance report roche group notes roche group consolidated financial statements accounts payable accounts payable millions chf trade payables taxes payable dividends payable payables total accounts payable noncurrent liabilities noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities longterm liabilities mainly related accrued employee benefits longterm genentech property purchase option exercise obligation see note current liabilities current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued chargebacks allowances accrued royalties commissions accrued liabilities total current liabilities accrued liabilities include shortterm genentech property purchase option exercise obligation see note roche finance report notes roche group consolidated financial statements roche group provisions contingent liabilities provisions movements recognised liabilities millions chf legal environmental restructuring employee provisions provisions provisions provisions provisions total year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration currency translation effects december current noncurrent december year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration movements currency translation effects december current noncurrent december expected outflow resources within one year one two years two three years three years december legal provisions legal provisions consist number separate legal matters including claims arising trade various group companies nature amounts timings outflows difficult predict legal expenses totalled chf million chf million reflect recent developments various legal matters details major legal cases outstanding disclosed roche finance report roche group notes roche group consolidated financial statements environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts timings outflows difficult predict significant provisions discounted time value money material significant provisions relate us site nutley new jersey estimated remediation costs landfill site near grenzach germany used manufacturing operations closed years ago estimated remediation costs manufacturing site clarecastle ireland see note restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group timings cash outflows reasonably certain provisions discounted time value money material matters pharmaceuticals division significant provisions relate strategic realignment manufacturing network including exiting four manufacturing sites see note research development strategic realignment field force reduction europe asiapacific regions employee provisions mostly relate certain employee benefit obligations sabbatical leave longservice benefits timings cash outflows reasonably estimated based past experience provisions timing cash outflows nature uncertain provisions relate items shown table provisions millions chf sales returns contingent consideration items total provisions contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimates future commitments payments given note roche finance report notes roche group consolidated financial statements roche group pharmaceuticals legal cases accutane hoffmannla roche inc hlr various roche affiliates named defendants numerous legal actions us elsewhere relating acne medication accutane litigation alleges accutane caused certain serious conditions including limited inflammatory bowel disease ibd birth defects psychiatric disorders hlr announced following reevaluation portfolio medicines available generic manufacturers rapidly declining brand sales us high costs personalinjury lawsuits continues defend vigorously decided immediately discontinue manufacture distribution product us actions pending federal court alleging ibd consolidated pretrial proceedings multidistrict litigation mdl us district court middle district florida tampa division august mdl closed pendency mdl district court granted summary judgment favour hlr federal ibd cases proceeded affirmed us court appeals eleventh circuit actions pending state court new jersey alleging ibd consolidated pretrial proceedings superior court new jersey law division atlantic county since january approximately cases dismissed us december hlr defending approximately actions involving approximately plaintiffs brought various federal state courts throughout us personal injuries allegedly resulting use accutane february superior court new jersey law division atlantic county held eightday evidentiary hearing whether plaintiffs experts testify accutane causes crohns disease february superior court barred plaintiffs experts methods meet requirements scientific reliability may superior court entered order dismissing prejudice agreedupon list crohns disease cases subject superior courts february order may superior court entered order granting summary judgment dismissing cases filed new jersey residents basis drug label adequate matter law since july superior court granted hlrs motion summary judgment adequacy label post ingestion cases jurisdictions superior court applied new jersey law jurisdictions granted hlrs motion dismissing approximately cases alternative superior court applied home state law granted summary judgment jurisdictions denied jurisdictions would resulted cases dismissed plaintiffs appealed decisions related crohns disease drug label december juries new jersey superior court ruled favour plaintiff eight cases assessing compensatory damages totalling usd million eight cases ruled favour plaintiff superior court hlr process appealing three cases usd million five cases verdicts reversed favour hlr usd million one case usd million appeal new jersey supreme court additional trials may scheduled individual trial results depend variety factors including many unique particular case therefore trial results date may predictive future trial results group continues defend vigorously remaining personal injury cases claims avastinlucentis investigations february italian antitrust authority agcm announced investigation determine whether roche genentech novartis entered agreement restrict competition italian market drugs reference particular avastin marketed roche lucentis marketed novartis avastin lucentis two different drugs developed approved different therapeutic purposes contain different active pharmaceutical ingredients march agcm issued verdict alleges roche novartis colluded artificially differentiate avastin lucentis order foster sales lucentis italy agcm fined roche eur million novartis eur million roche appealed agcm verdict tribunale amministrativo regionale del lazio tar december tar upheld decision agcm roche strongly disagrees verdict tar appealed may italian ministry health notified roche spa intention seek damages related matter july roche paid eur million fine protest avoid additional penalty fees recorded expense within general administration fine related interest reimbursed roche wins case outcome matters determined time tarceva subpoena november genentech received subpoena us department justice doj requesting documents information related promotion tarceva prescription product initially approved treatment locally advanced metastatic nonsmall cell lung cancer failure least one prior chemotherapy regimen later approved additional indications genentech cooperating associated investigation may government representatives presented first time governments civil liability theory specifically genentech allegedly participated offlabel promotion tarceva causing submission false claims reimbursement civil false claims act august government closed criminal investigation genentech genentech continues discussions government civil liability theory outcome matter determined time roche finance report roche group notes roche group consolidated financial statements rituxan arbitration october genentech biogen idec inc filed complaint california sanofiaventis deutschland gmbh sanofiaventis us llc sanofiaventis us inc sanofi seeking declaratory judgment certain genentech products including rituxan infringe sanofis us patent nos patents invalid sanofi alleged rituxan another genentech product infringe certain claims patents march district court ruled matter law genentech biogen idec infringe asserted patent claims may sanofi appealed courts noninfringement ruling appellate court affirmed district courts judgment patent infringement addition october sanofi affiliate hoechst gmbh hoechst filed icc international court arbitration paris request arbitration genentech relating terminated patentlicence agreement one hoechsts predecessors genentech pertained abovementioned patents related patents outside us hoechst sought payment patent licence royalties sales certain genentech products including rituxan damages breach contract relief various arbitral awards september february arbitrator found genentech liable hoechst patentlicence royalties rituxan awarded royalties interest hoechst sought february group recorded back royalty expense chf million net assumed reimbursement portion groups obligation copromotion partner us hoechst initiated proceedings us france germany seeking enforce arbitral awards october genentech paid awarded royalties interest hoechst protest genentech seeking annulment arbitral awards proceedings initiated court appeal paris hearing proceedings june september paris court appeal stayed annulment proceedings seek guidance eu court justice specific legal question raised genentech relating arbitral awards noncompliance eu competition laws november hoechst filed notices appeal french supreme court seeking review paris court appeals decision seek guidance eu court justice november french supreme court denied hoechsts challenge decision paris court appeals refer specific legal question eu court justice eu court justice held hearing january judgment expected later outcome matter determined time average wholesale prices litigation hlr roche laboratories inc rli along approximately brand generic pharmaceutical companies named defendants several legal actions us relating pricing pharmaceutical drugs state medicaid reimbursement primary allegation litigations pharmaceutical companies misrepresented otherwise reported inaccurate average wholesale prices awp andor wholesale acquisition costs wac drugs prices allegedly relied upon states calculating medicaid reimbursements entities retail pharmacies states respective attorney general seeking repayment amounts claim overreimbursed time period associated cases december hlr rli defending one awp action filed state new jersey hlr rli vigorously defending trial date set outcome matter determined time boniva litigation hlr genentech various roche affiliates collectively roche named defendants numerous legal actions us canada relating postmenopausal osteoporosis medication boniva litigations plaintiffs allege boniva caused either osteonecrosis jaw atypical femoral fractures december roche defending approximately actions involving approximately plaintiffs brought federal state courts throughout us one action brought court queens bench province saskatchewan canada personal injuries allegedly resulting use boniva cases early discovery stages litigation individual trial results depend variety factors including many unique particular case roche vigorously defending matters outcome matters determined time ema investigation october european medicines agency ema announced would start infringement procedure investigate allegations regarding alleged breach medicines safety reporting obligations relation centrally authorised medicines november ema announced results pharmacovigilance risk assessment committee assessment roches medicines ema found impact regarding benefitrisk balance roches medicines confirmed benefitrisk profiles based available safety information ema health authorities confirmed medicines remain authorised without changes treatment advice patients healthcare professionals corrective preventative actions resulting inspections implemented reinspection authorities november led certain findings roche addressing april ema issued report european commission summarises emas findings relation investigation july european commission issued notification ema returning case file ema new period inquiry ema year adopt revised report submission european commission outcome matter determined time roche finance report notes roche group consolidated financial statements roche group debt debt movements carrying value recognised liabilities millions chf january proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt net gains losses redemption repurchase bonds notes loss major debt restructuring amortisation debt discount business combinations net foreign currency transaction gains losses currency translation effects december bonds notes commercial paper amounts due banks financial institutions finance lease obligations borrowings total debt longterm debt shortterm debt total debt pledges groups assets connection debt roche finance report roche group notes roche group consolidated financial statements bonds notes recognised liabilities effective interest rates bonds notes millions chf effective interest rate underlying including instrument hedging us dollar notes fixed rate notes due september principal usd billion isin usbc notes due march principal usd billion outstanding usd billion isin usuam usas notes due september principal usd billion isin usba notes due september principal usd billion isin usbb na notes due september principal usd billion isin usbe na notes due november principal usd billion isin usbj na notes due march principal usd billion outstanding usd billion isin usuan usau na notes due november principal usd billion isin usbh na us dollar notes floating rate notes due september principal usd billion isin usbd na notes due september principal usd billion isin usaz na euro medium term note programme fixed rate notes due march principal gbp billion isin xs notes due march principal eur billion outstanding eur billion isin xs notes due june principal eur billion isin xs na notes due march principal usd million isin xs notes due march principal eur billion outstanding eur billion isin xs notes due august principal gbp million outstanding gbp million isin xs na notes due february principal eur billion isin xs na swiss franc bonds fixed rate bonds due march principal chf billion isin ch na bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch genentech senior notes senior notes due july principal usd billion isin usag na senior notes due july principal usd million outstanding usd million isin usac na total bonds notes roche finance report notes roche group consolidated financial statements roche group bonds notes maturity millions chf within one year one two years two three years three four years four five years five years total bonds notes unamortised discount included carrying value bonds notes millions chf us dollar notes euro notes swiss franc bonds pound sterling notes total unamortised discount issuance bonds notes february group issued eur billion fixed rate notes coupon euro medium term note programme notes mature february listed luxembourg stock exchange group received chf million aggregate net proceeds issuance sale fixed notes march group issued usd million fixed rate notes coupon euro medium term note programme notes mature march listed luxembourg stock exchange group received chf million aggregate net proceeds issuance sale fixed notes november group completed offering usd billion fixed rate notes coupon notes mature november group received chf million aggregate net proceeds issuance sale fixed notes major debt restructuring september group decided major debt restructuring group raised net proceeds chf million debt offering described newly issued debt senior unsecured guaranteed roche holding ltd group repurchased usd million fixed rate notes due march usd million fixed rate notes due march usd million fixed rate genentech senior notes due july eur million fixed rate notes due march major debt restructuring resulted loss repurchase chf million issuance bonds notes intermune acquisition september group financed intermune acquisition see note combination groups funds debt securities commercial paper group raised net proceeds approximately chf billion debt offering described newly issued debt senior unsecured guaranteed roche holding ltd roche finance report roche group notes roche group consolidated financial statements september group completed offering us dollar notes received chf million aggregate net proceeds issuance sale fixed floating rate notes terms proceeds notes follows issuance us dollar fixed floating rate notes principal amount net proceeds usd millions chf millions floating rate notes due floating rate notes due fixed rate notes due fixed rate notes due fixed rate notes due fixed rate notes due total major debt restructuring november group major debt restructuring group raised net proceeds approximately chf billion debt offering described newly issued debt senior unsecured guaranteed roche holding ltd debt used repurchase usd million fixed rate genentech senior notes due july usd million fixed rate notes due march major debt restructuring resulted loss repurchase chf million november group completed offering us dollar notes received chf million aggregate net proceeds issuance sale fixed rate notes terms proceeds notes follows issuance us dollar fixed rate notes principal amount net proceeds usd millions chf millions fixed rate notes due fixed rate notes due total redemption repurchase bonds notes partial redemption us dollar notes december group resolved exercise option call early partial redemption fixed rate notes due march march group redeemed outstanding principal usd million amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal cash outflow chf million plus accrued interest additional chf million loss recorded redemption effective interest rate notes september group completed tender offer repurchase usd million fixed rate notes due march cash outflow chf million plus accrued interest loss repurchase chf million effective interest rate notes september group completed tender offer repurchase usd million fixed rate notes due march cash outflow chf million plus accrued interest loss repurchase chf million effective interest rate notes redemption pound sterling notes due date march group redeemed fixed rate notes principal gbp million cash outflow chf million plus accrued interest effective interest rate notes redemption genentech senior notes due date july group redeemed fixed rate senior notes principal usd billion cash outflow chf million plus accrued interest effective interest rate notes partial repurchase genentech senior notes september group repurchased usd million fixed rate senior notes due july cash outflow chf million plus accrued interest loss repurchase chf million effective interest rate notes roche finance report notes roche group consolidated financial statements roche group partial repurchase euro notes november group repurchased eur million fixed rate notes due march cash outflow chf million plus accrued interest loss repurchase chf million effective interest rate notes early partial redemption us dollardenominated notes december group resolved exercise option call early partial redemption fixed rate notes due march group redeem outstanding principal usd million march amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal cash outflow approximately usd million plus accrued interest expected redemption group revised carrying value notes take account changes amounts timings estimated cash flows revised carrying value notes december usd million chf million increase carrying value usd million chf million recorded within financing costs see note loss redemption effective interest rate notes redemption repurchase bonds notes group completed early repurchase gbp million fixed rate notes completed early redemption usd billion fixed rate notes cash flows issuance redemption repurchase bonds notes cash inflows issuance bonds notes millions chf euro medium term note programme euro notes euro medium term note programme us dollar notes us dollar notes total cash inflows issuance bonds notes cash outflows redemption repurchase bonds notes millions chf euro medium term note programme pound sterling notes euro medium term note programme euro notes us dollar notes total cash outflows redemption repurchase bonds notes commercial paper roche holdings inc commercial paper program roche holdings inc established commercial paper program issue usd billion unsecured commercial paper notes guaranteed roche holding ltd second half existing committed credit line available backstop supporting commercial paper program changed eur billion usd billion new committed credit line usd billion added total committed credit lines available backstop supporting commercial paper program usd billion december maturity notes program exceed days date issuance december unsecured commercial paper notes principal amount usd billion average interest rate outstanding movements commercial paper obligations millions chf january net cash proceeds payments currency translation effects december roche finance report roche group notes roche group consolidated financial statements amounts due banks financial institutions amounts denominated various currencies notably chinese renminbi argentine peso average interest rate december amounts outstanding chf million chf million due within one year equity attributable roche shareholders changes equity attributable roche shareholders millions chf reserves retained share capital earnings fair value hedging translation total year ended december january net income recognised income statement availableforsale investments fair value gains losses taken equity transferred income statement income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests december entire amount transferred income statement reported financial income expense roche finance report notes roche group consolidated financial statements roche group changes equity attributable roche shareholders millions chf reserves retained share capital earnings fair value hedging translation total year ended december january net income recognised income statement availableforsale investments fair value gains losses taken equity transferred income statement income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests december entire amount transferred income statement reported financial income expense genentech transaction group completed purchase noncontrolling interests genentech effective march based international accounting standard separate financial statements ias consistent international financial reporting standard consolidated financial statements ifrs adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group time reduced chf billion chf billion allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacted groups net equity effect groups business dividend policy roche finance report roche group notes roche group consolidated financial statements share capital december authorised issued share capital roche holding ltd groups parent company consisted million shares nominal value chf preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares march shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition shareholder group pooled voting rights holds shares corresponding shares issued figure include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool described note based information supplied group novartis ltd basel affiliates participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends march shareholders approved distribution dividend chf per share nonvoting equity security chf respect business year distribution holders outstanding shares nonvoting equity securities totalled chf million chf million recorded retained earnings board directors proposed dividends business year chf per share nonvoting equity security approved would result total distribution shareholders chf million subject approval annual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities millions millions shares nonvoting equity securities total equity instruments recorded within equity original purchase cost december fair value shares chf million nonvoting equity securities chf billion equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note reserves fair value reserve fair value reserve represents cumulative net change fair value availableforsale financial assets asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs roche finance report notes roche group consolidated financial statements roche group subsidiaries chugai effective october roche group chugai completed alliance create leading researchdriven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai consolidated subsidiary chugai fully consolidated subsidiary group based groups interest chugai december roche relationship chugai founded basic alliance licensing research collaboration agreements common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements accordance international financial reporting standards ifrs filed quarterly basis tokyo stock exchange due certain consolidation entries minor differences chugais standalone ifrs results results chugai consolidated roche group accordance ifrs chugai summarised financial information millions chf income statement sales royalties operating income total revenues operating profit balance sheet noncurrent assets current assets noncurrent liabilities current liabilities total net assets cash flows cash flows operating activities cash flows investing activities cash flows financing activities dividends dividends distributed third parties holding chugai shares totalled chf million chf million recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany items roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less roche finance report roche group notes roche group consolidated financial statements licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai also right first refusal development marketing japan development compounds advanced roche rest world umbrella rights agreement excluding japan south korea signed may revised amended restated rest world umbrella rights agreement excluding japan south korea taiwan signed august agreement roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea taiwan agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result payments arms length basis roche chugai following matters upfront payments right first refusal licence product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements arms length basis research collaboration agreements roche chugai entered research collaboration agreements areas small molecule synthetic drug research biotechnologybased drug discovery foundation medicine april group acquired controlling interest foundation medicine inc fmi entered investor rights agreement research development collaboration agreement several commercial collaboration agreements consolidated subsidiary fmi fully consolidated subsidiary group based groups interest fmi december roche relationship fmi founded agreements common stock fmi publicly traded listed nasdaq stock code fmi fmi prepares financial statements accordance us gaap filed quarterly basis sec due certain consolidation entries differences fmis standalone us gaap results results fmi consolidated roche group accordance ifrs dividends dividends distributed third parties holding fmi shares divestment subsidiary april group sold wholly owned subsidiary marcadia biotech inc third party part previously announced pharmaceuticals divisions research development reorganisation total consideration received usd million convertible note total loss divestment chf million reported global restructuring costs roche pharmaceuticals operating segment shown table october convertible note repaid group received usd million cash recognised gain usd million loss divestment subsidiary millions chf consideration intangible assets total net assets disposed loss divestment subsidiary roche finance report notes roche group consolidated financial statements roche group noncontrolling interests changes equity attributable noncontrolling interests millions chf january net income recognised income statement chugai noncontrolling interests total net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans comprehensive income net tax total comprehensive income business combinations dividends noncontrolling shareholders chugai noncontrolling interests equity compensation plans net transactions equity changes noncontrolling interests equity contribution noncontrolling interests december chugai noncontrolling interests total noncontrolling interests employee benefits employee remuneration millions chf wages salaries social security costs defined contribution plans operating expenses defined benefit plans equity compensation plans termination costs employee benefits employee remuneration included operating results net interest cost defined benefit plans total employee remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits roche finance report roche group notes roche group consolidated financial statements pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees time ensuring various plans appropriately financed managing potential impacts groups longterm financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements market practice countries employees employed postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans defined contribution plans defined contribution plans funded payments employees group funds administered third parties groups expenses plans chf million chf million assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions groups major defined contribution plans us notably us roche k savings plan defined benefit plans plans usually established trusts independent group funded payments group companies employees cases notably major defined benefit plans germany plans unfunded group pays pensions retired employees directly financial resources plans usually governed senior governing body board trustees typically composed employee employer representatives funding plans determined local regulations using independent actuarial valuations separate independent actuarial valuations together semiannual update prepared accordance requirements ias use groups financial statements groups major pension plans located switzerland us germany total account groups defined benefit obligation pension plans switzerland current pension arrangements employees switzerland made plans governed swiss federal occupational old age survivors disability pension act bvg groups pension plans administered separate legal foundations funded regular employee company contributions final benefit contributionbased certain minimum guarantees due minimum guarantees swiss plans treated defined benefit plans purposes ifrs financial statements although many characteristics defined contribution plans underfunding may remedied various measures increasing employee company contributions lowering interest rate retirement account balances reducing prospective benefits suspension early withdrawal facility pension plans us groups major defined benefit plans us closed new members since new employees us join defined contribution plan largest remaining defined benefit plans funded pension plans including separate plans originating nutley palo alto indianapolis sites together smaller unfunded supplementary retirement plans benefits based highest average annual rate earnings specified period length employment plans noncontributory employees group making periodic payments plans payments made group usd million usd million underfunding would normally remedied additional company contributions pension plans germany groups major pension arrangements germany governed occupational pensions act betravg plans unfunded group pays pensions retired employees directly financial resources plans noncontributory employees benefits based final salary length employment plans closed new members since replaced new plan funded regular employee company contributions administered contractual trust agreement final benefit contributionbased minimum guarantee due minimum guarantee plan treated defined benefit plan purposes ifrs financial statements although many characteristics defined contribution plan roche finance report notes roche group consolidated financial statements roche group pension plans rest world represent approximately groups defined benefit obligation consist number smaller plans various countries largest pension plans chugai independently managed chugai main pension plan united kingdom chugai plans fully described chugais ifrs financial statements uk pension plan funded regular employee company contributions benefits based final salary length employment plan closed new members since replaced defined contribution plan postemployment benefit opeb plans represent approximately groups defined benefit obligation consist mostly postretirement healthcare life insurance schemes mainly us plans mainly unfunded contributory employees group reimbursing retired employees directly financial resources groups major defined benefit opeb plans us closed new members since part costs plans reimbursable medicare prescription drug improvement modernization act statutory funding requirement plans group funding plans extent tax efficient payments made group plans none december ifrs funding status including reimbursement rights funded opeb plans us defined benefit plans income statement millions chf post post pension employment total pension employment total plans benefit plans expense plans benefit plans expense current service cost past service income cost settlement gain loss total operating expenses net interest cost defined benefit plans total expense recognised income statement funding status funding groups various defined benefit plans responsibility senior governing body board trustees sponsoring employer managed based local statutory valuations follow legislation requirements respective jurisdiction plan established qualified independent actuaries carry statutory actuarial valuations regular basis actuarial assumptions determining funding status statutory basis regularly assessed local senior governing body funding status closely monitored corporate level unfunded plans mainly groups german affiliates fully reserved pension obligations invested local affiliates operations ifrs funded status funded defined benefit plans remained stable reimbursement rights linked postemployment medical plans us represent expected reimbursement medical expenditure provided medicare prescription drug improvement modernization act roche finance report roche group notes roche group consolidated financial statements defined benefit plans funding status millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability reported balance sheet defined benefit plan assets defined benefit plan liabilities plan assets responsibility investment strategies funded plans senior governance body board trustees asset liability studies performed regularly major pension plans studies examine obligations postretirement benefit plans evaluate various investment strategies respect key financial measures expected returns expected risks expected contributions expected funded status plan interdependent way goal assetliability study select appropriate asset allocation funds held within plan investment strategy developed optimise expected returns manage risks contain fluctuations statutory funded status assetliability studies include strategies match cash flows assets plan obligations group currently use annuities longevity swaps manage longevity risk plan assets managed using internal external asset managers actual performance continually monitored pension fund governance bodies well closely monitored corporate level financial statements difference interest income actual return plan assets remeasurement recorded directly comprehensive income actual return plan assets loss chf million gain chf million recognition pension assets limited present value economic benefits available refunds plans reductions future contributions plans defined benefit plans fair value plan assets reimbursement rights millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january interest income plan assets remeasurements plan assets currency translation effects employer contributions employee contributions benefits paid funded plans benefits paid settlements administration costs december roche finance report notes roche group consolidated financial statements roche group defined benefit plans composition plan assets millions chf equity securities debt securities property cash money market instruments investments december assets invested variety different classes order maintain balance risk return follows equity debt securities mainly quoted market prices level fair value hierarchy property mainly private commercial property funds mainly observable inputs level fair value hierarchy cash money market instruments mainly invested financial institutions credit rating lower investments mainly consist alternatives mortgages commodities insurance contracts used risk management purposes mainly observable inputs level fair value hierarchy unobservable inputs level fair value hierarchy included within fair value plan assets groups shares nonvoting securities fair value chf million chf million debt instruments issued group fair value chf million chf million defined benefit obligation defined benefit obligation calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth mortality rates present value defined benefit obligation determined discounting estimated future cash outflows using interest rates highquality corporate bonds government bonds countries deep market corporate bonds corporate government bonds denominated currency benefits paid maturity terms approximating terms related pension obligation groups final salarybased defined benefit pension plans us germany united kingdom closed new participants active employees members pension plans time closed new participants continue accrue benefits final salarybased defined benefit pension plans new employees us uk join groups defined contribution plans new employees germany join contributionbased plan minimum guarantee defined benefit pension plans switzerland final benefit contributionbased minimum guarantee remain open new employees result proportion defined benefit obligation relates closed plans expected decrease future roche finance report roche group notes roche group consolidated financial statements defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january current service cost interest cost remeasurements demographic assumptions financial assumptions experience adjustments currency translation effects movements employee contributions benefits paid funded plans benefits paid unfunded plans benefits paid settlements past service income cost settlement gain loss december composition plan active members deferred vested members retired members december plans geography switzerland united states germany rest world december duration years actuarial assumptions actuarial assumptions used financial statements based requirements set ias employee benefits unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management based advice actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters interest rates salary benefit levels inflation rates costs medical benefits actuarial assumptions vary based upon local economic social conditions actuarial assumptions used various statutory valuations may differ based local legal regulatory requirements roche finance report notes roche group consolidated financial statements roche group demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes increases longevity rates employee turnover disability early retirement based historical behaviour within group companies average life expectancy assumed individual age follows defined benefit plans average life expectancy major schemes years male female country mortality table switzerland bvg generational tables united states rp projected mp germany heubeck tables g financial assumptions based market expectations period obligations settled assumptions used actuarial valuations shown defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates salary increases expected rates pension increases expected inflation rates immediate medical cost trend rate ultimate medical cost trend rate discount rates determined reference interest rates highquality corporate bonds government bonds countries deep market corporate bonds expected rates salary increases based expected inflation rates adjustment reflect groups latest expectation longterm real salary increases expected rates pension increases generally linked expected inflation rate funding status plan expected inflation rates derived looking level inflation implied financial markets conjunction economists price inflation forecasts historic price inflation well economic variables circumstances medical cost trend rates take account benefits set plan terms expected future changes medical costs since groups major postemployment medical plans us employees rates driven developments us sensitivity analysis measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions following table summarises impact change assumptions present value defined benefit obligation defined benefit plans sensitivity defined benefit obligation actuarial assumptions millions chf year increase life expectancy discount rates increase decrease expected inflation rates increase decrease immediate medical cost trend rate increase decrease sensitivity analysis considers change one assumption time leaving assumptions unchanged approach shows isolated effect changing one individual assumption take account assumptions related method used carry sensitivity analysis prior year roche finance report roche group notes roche group consolidated financial statements cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions net reimbursements funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately chf million includes estimated chf million additional contributions mostly related us defined benefit plans benefits paid unfunded plans estimated approximately chf million mostly relate german defined benefit plans equity compensation plans group operates several equity compensation plans including separate plans chugai foundation medicine ifrs share based payment requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expenses equity compensation plans roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan roche connect roche option plan bonus stock awards chugai foundation medicine plans total operating expenses equitysettled cashsettled roche finance report notes roche group consolidated financial statements roche group cash inflow outflow equity compensation plans millions chf roche option plan exercises chugai foundation medicine exercises roche connect costs transactions equity total cash inflow outflow equitysettled equity compensation plans net transactions equity net cash outflow transactions equity mainly arises sales purchases equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note equity compensation plans roche stocksettled stock appreciation rights group issues stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive nonvoting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date roche ssar plan million ssars available issuance tenyear period rights nontradable equitysettled awards sevenyear duration vest phased basis three years roche ssars movement number rights outstanding weighted average weighted average number rights exercise price number rights exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable number weighted average weighted average number weighted average outstanding years remaining exercise price exercisable exercise price year grant thousands contractual life chf thousands chf total roche restricted stock unit plan group issues restricted stock units rsus awards certain directors management employees selected discretion group rsus nontradable represent right receive nonvoting equity securities vest threeyear period subject performance conditions currently performance conditions outstanding rsus december roche rsu plan million nonvoting equity securities available issuance tenyear period roche rsu plan also includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award granted roche finance report roche group notes roche group consolidated financial statements roche rsus movement number awards outstanding number awards number awards thousands thousands outstanding january granted forfeited transferred participants outstanding december vested transferable roche performance share plan group offers future share nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers nontradable equitysettled awards programme currently operates annual threeyear cycles roche performance share plan psp includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number shares nonvoting equity securities individual award granted amount shares nonvoting equity securities allocated depend upon individuals salary level achievement performance targets linked groups total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors award result zero two shares non voting equity securities value adjustment depending upon achievement performance targets roche performance share plan terms outstanding awards december number awards outstanding thousands vesting period years years years allocated recipients feb feb feb fair value per unit grant chf total fair value grant chf millions roche connect programme enables employees worldwide except us certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held million nonvoting equity securities million cost plan chf million chf million roche option plan programme used countries ssars used awards plan give employees right purchase nonvoting equity securities exercise price specified grant date options nontradable equity settled awards sevenyear duration vest phased basis three years roche option plan movement number options outstanding weighted average weighted average number options exercise price number options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche finance report notes roche group consolidated financial statements roche group roche option plan terms options outstanding december options outstanding options exercisable weighted average weighted average weighted average number outstanding years remaining exercise price number exercisable exercise price year grant thousands contractual life chf thousands chf total weighted average share price roche nonvoting equity securities year chf chf bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year issued end april number awards fair value per award calculated grant date fair value measurement inputs used measurement fair values grant date equity compensation plans follows fair value measurement roche stocksettled roche stock appreciation roche restricted performance share roche option rights stock unit plan plan plan progressively cliff vesting cliff vesting progressively vesting period years years years years contractual life years na na years number granted year thousands weighted average fair value chf model used binomial market pricea monte carlob binomial inputs option pricing model share price grant date chf exercise price chf expected volatility c na na expected dividend yield na na early exercise factor na na expected exit rate na na fair value roche rsus equivalent share price date grant b input parameters covariance matrix roche individual companies peer group based threeyear history riskfree rate minus valuation takes account defined rank performance structure determines payout plan c volatility determined primarily reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour roche finance report roche group notes roche group consolidated financial statements earnings per share nonvoting equity security basic earnings per share nonvoting equity security net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number shares nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security net income attributable roche shareholders chf millions increase noncontrolling interests share group net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf roche finance report notes roche group consolidated financial statements roche group statement cash flows cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics businesses calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown statement cash flows operating cash flows also include income taxes paid activities cash generated operations millions chf net income add back nonoperating income expense financing costs financial income expense income taxes operating profit depreciation property plant equipment amortisation intangible assets impairment goodwill impairment intangible assets impairment reversal property plant equipment operating income expense defined benefit plans operating expense equitysettled equity compensation plans net income expense provisions bad debt reversal expense inventory writedowns inventory fair value adjustment net gain loss disposal products adjustments cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total roche finance report roche group notes roche group consolidated financial statements cash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity dividends paid millions chf dividends roche group shareholders dividends noncontrolling shareholders chugai dividends noncontrolling shareholders increase decrease dividends payable dividend withholding tax total significant noncash transactions significant noncash transactions none except contingent consideration arrangements arising business combinations see notes genentech property purchase option exercise see note roche finance report notes roche group consolidated financial statements roche group risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part business planning controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties financial risk management within group governed policies reviewed boards directors roche chugai foundation medicine appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits type authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche chugai foundation medicine credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying value groups financial assets accounts receivable december group trade receivables chf billion chf billion subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective trade receivables management maximise collection unpaid amounts december groups combined trade receivables balance three us national wholesale distributors amerisourcebergen corp mckesson corp cardinal health inc equivalent chf billion representing groups consolidated trade receivables chf billion representing significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral held trade receivables none since financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries trade receivables chf billion chf billion public private customers countries group uses different measures improve collections countries including intense communication customers factoring negotiations payments plans charging interest late payments legal action roche finance report roche group notes roche group consolidated financial statements nature geographic location counterparties accounts receivable overdue impaired shown table include balances us national wholesalers southern europe public customers described accounts receivable overdue nature geographical location counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland europe north america latin america japan asia australia oceania rest world total ageing accounts receivable impaired shown table ageing accounts receivable impaired millions chf neither overdue impaired overdue month overdue months overdue months overdue months overdue year total accounts receivable cash marketable securities december group cash marketable securities chf billion chf billion subject policy restricting exposures highquality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly investments marketable securities entered basis guidelines regard liquidity quality maximum amount general rule group invests highquality securities adequate liquidity cash shortterm time deposits subject rules limit groups exposure individual financial institutions rating analysis cash fixed income marketable securities market values chf total chf total aaarange aarange arange bbbrange bbbrange unrated total roche finance report notes roche group consolidated financial statements roche group master netting agreements group enters derivative transactions collateral agreements international swaps derivatives association isda master netting agreements respective counterparties order mitigate counterparty risk agreements amounts owed counterparty single day respect transactions outstanding currency aggregated single net amount payable one party isda agreements meet criteria offsetting balance sheet group currently enforceable right offset recognised amounts right offset enforceable occurrence future events default credit events contract terms december significant financial assets whose terms renegotiated none impairment losses total impairment losses availableforsale financial assets amounted chf million chf million liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time roche chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements december group unused committed credit lines various financial institutions totalling chf billion chf billion chf billion serve backstop line commercial paper program remaining undiscounted cash flow contractual maturities financial liabilities including estimated interest payments shown table contractual maturities financial liabilities millions chf carrying less value total year years years years year ended december debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities year ended december debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities takeorpay commitments group entered contract manufacturing agreements various companies develop manufacturing capacity flexibility future minimum takeorpay commitments within agreements total potential commitment group chf billion december mainly related contract manufacturing agreement pharmaceuticals division effect roche finance report roche group notes roche group consolidated financial statements market risk market risk arises changing market prices mainly foreign exchange rates interest rates groups financial assets financial liabilities affect groups financial result equity valueatrisk group uses valueatrisk var measure impact market risk financial instruments var indicates value range within given financial instrument fluctuate preset probability result movements market prices var calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period trading days past ten years holding period reflects time required change corresponding risk exposure deemed appropriate actual future gains losses associated treasury activities may differ materially var analyses due inherent limitations associated predicting timing amount changes interest rates foreign exchange rates equity investment prices particularly periods high market volatilities furthermore var include effect changes credit spreads market risk financial instruments millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component remained largely stable foreign exchange component increased due unfavourable exposure mix price component arises mainly movements equity security prices increased due higher market value equity securities held group foreign exchange risk group uses swiss franc reporting currency result exposed movements foreign currencies mainly us dollar japanese yen euro objective groups foreign exchange risk management activities preserve economic value current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group uses forward contracts foreign exchange options crosscurrency swaps hedge transaction exposures application instruments intends continuously lock favourable developments foreign exchange rates thereby reducing exposure potential future movements rates interest rate risk group mainly raises debt fixed rate basis bonds notes group exposed movements interest rates mainly us dollar swiss franc euro floating rate financial instruments primary objective groups interest rate management protect net interest result group may use forward contracts options swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposures roche finance report notes roche group consolidated financial statements roche group price risk price risk arises mainly movements prices equity securities group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments capital management group defines capital manages groups total capitalisation sum debt plus equity including non controlling interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events capitalisation reported senior management part groups regular internal management reporting shown table capital millions chf capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity total debt capitalisation groups net equity significantly impacted genentech transaction see note group subject regulatory capital adequacy requirements known financial services industry group majority shareholdings chugai foundation medicine see note chugai foundation medicine public companies objectives policies processes managing capital determined local management roche finance report roche group notes roche group consolidated financial statements financial instrument accounting classifications fair values fair values financial assets liabilities together carrying value shown consolidated balance sheet follows carrying value fair value financial instruments millions chf fair value total available hedging fair value loans financial carrying forsale instruments designated receivables liabilities value fair value year ended december noncurrent assets availableforsale investments financial noncurrent assets accounts receivable marketable securities cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities year ended december noncurrent assets availableforsale investments financial noncurrent assets accounts receivable marketable securities cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities fair value bonds notes level calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods roche finance report notes roche group consolidated financial statements roche group fair value hierarchy table analyses financial instruments carried fair value valuation method different levels defined follows level quoted prices unadjusted active markets identical assets liabilities level observable inputs quoted prices active markets identical assets liabilities level unobservable inputs fair value hierarchy financial instruments millions chf level level level total year ended december marketable securities equity securities debt securities money market instruments time accounts three months derivative financial instruments availableforsale investments held fair value financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value year ended december marketable securities equity securities debt securities money market instruments time accounts three months derivative financial instruments availableforsale investments held fair value financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value level financial assets consist treasury bills bonds quoted shares level financial assets consist primarily commercial paper certificates deposit derivative financial instruments group determines level fair values using following valuation techniques marketable securities derivative financial instruments based valuation models use observable market data interest rates yield curves foreign exchange rates implied volatilities similar instruments measurement date availableforsale investments using valuation model derived recently published observable financial prices group recognises transfers levels fair value hierarchy end reporting period transfer occurred significant transfers level level vice versa year none roche finance report roche group notes roche group consolidated financial statements level fair values details determination level fair value measurements transfer level fair value hierarchy set contingent consideration arrangements millions chf january arising business combinations acquired business combinations utilised total unrealised gains losses included income statement unused amounts reversed additional amount created discount unwind total gains losses included comprehensive income currency translation effects december contingent consideration arrangements group party certain contingent consideration arrangements arising business combinations fair values determined considering expected payments discounted present value using riskadjusted average discount rate expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario significant unobservable inputs forecast sales performance criteria riskadjusted discount rate estimated fair value would increase forecast sales performance criteria rate higher riskadjusted discount rate lower december total potential payments contingent consideration arrangements could chf billion chf billion follows potential payments contingent consideration arrangements millions chf acquisition year acquired operating segment seragon roche pharmaceuticals trophos roche pharmaceuticals dutalys roche pharmaceuticals santaris roche pharmaceuticals geneweave diagnostics genia diagnostics ariosa diagnostics cmi diagnostics iquum diagnostics others diagnostics december derivative financial instruments group entered various currency swaps certain nonus dollar debt instruments cash collateral agreements entered counterparties currency swaps mitigate counterparty risk following table sets carrying value derivative financial instruments amounts subject master netting agreements roche finance report notes roche group consolidated financial statements roche group derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts crosscurrency swaps interest rate derivatives swaps derivatives carrying value derivative financial instruments derivatives subject master netting agreements collateral arrangements net amount collateral arrangements fair value currency swaps decreased mainly due weaker euro compared us dollar result cash delivered group counterparties movements cash collateral receivable accrued liability millions chf january net cash delivered group december hedge accounting december group following cash flow hedges fair value hedges designated qualifying hedge relationship cash flow hedges group entered crosscurrency swaps hedge foreign exchange interest rate risk bonds notes issued group denominated euro pound sterling december instruments recorded net fair value liability chf million chf million ineffective portion chugai entered foreign exchange forward contracts hedge part foreign translation exposure swiss franc us dollar december instruments recorded fair value liabilities chf million chf million ineffective portion expected undiscounted cash flows qualifying cash flow hedges including interest payments duration derivative contract final settlement maturity shown table expected cash flows qualifying cash flow hedges millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow roche finance report roche group notes roche group consolidated financial statements undiscounted cash flows table affect profit loss shown include interest payments duration derivative contract include final settlement maturity expected cash flows qualifying cash flow hedges impact profit loss millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow changes hedging reserve within equity shown note fair value hedges group entered interest rate swaps hedge fixedterm debt instruments december instruments recorded fair value liabilities chf million chf million fair value assets chf million chf million gain chf million recorded interest rate swaps gain chf million fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments december group forward contracts manage risk market fluctuations equity investments various biotechnology companies forward contracts recorded fair value liabilities chf million december hedged equity investments sold forward contracts settled resulted loss forward contracts chf million loss chf million loss forward contracts offset gain sale hedged equity investments recorded net gains sale equity securities see note net investment hedges group net investment hedges related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool mr andr hoffmann dr andreas oeri members board directors roche holding ltd mr hoffmann received remuneration totalling chf chf dr oeri received remuneration totalling chf chf transactions group individual members shareholder group exception mr jrg duschmal works postdoc roche subsidiaries associates listing major group subsidiaries associates included note transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associates roche finance report notes roche group consolidated financial statements roche group key management personnel total remuneration key management personnel chf million chf million members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees dr franz members corporate executive committee roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members corporate executive committee members corporate executive committee also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note new members corporate executive committee included table full calendar year joined cec similarly members corporate executive committee retiring part way year included full calendar year left cec remuneration members board directors corporate executive committee millions chf salaries including cashsettled bonus bonus stock awards social security costs pensions postemployment benefits equity compensation plans board fees employee benefits total purposes remuneration disclosures values equity compensation plans including bonus stock awards calculated based fair value used note represent cost group awards grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions detailed disclosures regarding executive remuneration required swiss law included remuneration report included annual report pages disclosures values equity compensation plans including bonus stock awards represent fair value employee receives taking account preliminary assessment completed performance conditions fair values shown table reconciles disclosures required swiss law related party disclosures key management personnel reconciliation executive remuneration disclosures required swiss law millions chf total remuneration members board directors corporate executive committee ifrs basis see table deduct bonus stock awards ifrs basis equity compensation plans ifrs basis add back bonus stock awards swiss legal basis equity compensation plans swiss legal basis total remuneration members board directors corporate executive committee swiss legal basis including social security costs board directors annual report corporate executive committee pages annual report roche finance report roche group notes roche group consolidated financial statements bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year issued end april number awards fair value per award calculated grant date equity compensation plans members corporate executive committee received equity compensation shown following tables number rights options awards granted members corporate executive committee roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan contributions paid members corporate executive committee millions chf roche connect transactions former members board directors corporate executive committee pensions totalling chf million paid group former corporate executive committee members chf million subsequent retirement member board directors dr humer received chf million advisory capacity chairman board defined benefit plans transactions group various defined benefit plans employees group described note roche finance report notes roche group consolidated financial statements roche group subsidiaries associates listed companies share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange six swiss exchange zurich valor share valor genussschein isin share ch isin genussschein ch market capitalisation chf japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy united states foundation medicine inc cambridge usd stock exchange nasdaq stock code fmi market capitalisation usd nonlisted companies share capital equity interest country company city millions algeria roche algrie spa hydra dzd argentina productos roche sa qumica e industrial tigre ars vanguardia en productos farmacuticos vanprofarma sa buenos aires ars australia roche diabetes care australia pty limited bella vista aud roche diagnostics australia pty limited castle hill aud roche products pty limited dee aud austria dutalys gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostics gmbh vienna eur azerbaijan roche azerbaijan llc baku azn bangladesh roche bangladesh limited dhaka bdt belarus fllc roche products limited minsk byr belgium nv roche sa brussels eur roche diagnostics belgium nv brussels eur bermuda chemical manufacturing trading company limited hamilton usd hoffmannla roche products limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd bosniaherzegovina roche ltd pharmaceutical company sarajevo bam brazil produtos roche qumicos e farmacuticos sa paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john cad chile roche chile limitada santiago de chile clp china roche china holding ltd shanghai usd roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai limited shanghai usd roche diagnostics suzhou limited suzhou cny roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd roche finance report roche group notes roche group consolidated financial statements share capital equity interest country company city millions colombia productos roche sa bogot cop costa rica roche servicios sa heredia usd cte divoire roche cte divoire sarl abidjan xof croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche medicinalvarer og kemikalier hvidovre dkk roche diagnostics hvidovre dkk roche innovation center copenhagen hoersholm dkk dominican republic productos roche dominicana sa santo domingo dop ecuador roche ecuador sa quito usd egypt roche egypt manufacturing trading sae cairo egp roche egypt llc cairo egp rodiagnostics egypt trading sae giza egp el salvador productos roche el salvador sa san salvador svc estonia roche eesti tallinn eur finland roche diagnostics oy espoo eur roche oy espoo eur france institut roche sas boulognebillancourt eur roche diabetes care france sas meylan eur roche diagnostics france sas meylan eur roche sas boulognebillancourt eur trophos sa marseille eur ventana medical systems sas illkirch eur georgia roche georgia llc tbilisi gel germany ascur versicherungsvermittlungs gmbh grenzachwyhlen eur galenus mannheim pharma gmbh mannheim eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen eur roche diabetes care gmbh mannheim eur roche diagnostics deutschland gmbh mannheim eur roche diagnostics gmbh mannheim eur roche mtm laboratories ag mannheim eur roche pharma ag grenzachwyhlen eur roche pvt gmbh waiblingen eur roche real estate services mannheim gmbh mannheim eur signature diagnostics gmbh potsdam eur swisslab gmbh berlin eur verum diagnostica gmbh munich eur ghana roche products ghana limited accra ghs greece roche hellas sa athens eur roche diagnostics hellas sa athens eur guatemala productos roche guatemala sa guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostics india pvt ltd mumbai inr roche products india pvt ltd mumbai inr indonesia pt roche indonesia jakarta idr iran roche pars co ltd tehran irr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit ils roche pharmaceuticals israel ltd petach tikva ils italy roche diagnostics spa monza eur roche spa monza eur japan roche diagnostics kk tokyo jpy jordan f hoffmannla roche ltd jordan psc amman jod kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius ltl macedonia roche makedonija dooel skopje mkd malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd petaling jaya myr syntex pharmaceuticals sdn bhd kuala lumpur myr mauritius roche products mauritius limited quatre bornes mur mexico productos roche sa de cv mexico city mxn roche servicios de mxico sa de cv mexico city mxn roche finance report notes roche group consolidated financial statements roche group share capital equity interest country company city millions moldova roche products limited srl chisinau mdl morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherlands kapa biosystems bv amsterdam usd roche diabetes care nederland bv almere eur roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics nz limited auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche products limited lagos ngn norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr palestine roche pharmaceuticals palestine ltd ramallah albireh usd panama productos roche panam sa panama city pab productos roche interamericana sa panama city usd peru productos roche qumica farmacutica sa lima pen roche farma peru sa lima pen philippines roche philippines inc taguig city php poland roche diabetes care polska sp z oo warsaw pln roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd roche products inc ponce usd syntex puerto rico inc ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diagnostics rus moscow rub roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druzba doo ljubljana eur south africa kapa biosystems pty ltd cape town zar roche products proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain andreu roche sa madrid eur roche diabetes care spain sl barcelona eur roche diagnostics sl barcelona eur roche farma sa madrid eur sri lanka roche products colombo private limited colombo lkr sweden roche ab stockholm sek roche diagnostics scandinavia ab bromma sek switzerland biopharm ag basel chf f hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf intermune international ag basel chf museum tinguely ag basel chf phaor ag basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche chemische unternehmungen ag basel chf roche diabetes care ltd rotkreuz chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf syntex pharm ag basel chf tavero ag basel chf roche finance report roche group notes roche group consolidated financial statements share capital equity interest country company city millions taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey roche diagnostics turkey anonim sirketi istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah united arab emirates roche diagnostics middle east fzco dubai aed roche middle east fzco dubai aed united kingdom intermune holdings limited welwyn garden city gbp intermune uk limited welwyn garden city gbp intermune uk limited welwyn garden city gbp intermune bristol limited welwyn garden city gbp kapa biosystems ltd london gbp piramed limited welwyn garden city gbp roche diabetes care limited burgess hill gbp roche diagnostics ltd burgess hill gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp united states life sciences corporation little falls usd adheron therapeutics inc wilmington usd anadys pharmaceuticals inc south san francisco usd ariosa diagnostics inc san jose usd bina technologies inc belmont usd bioveris corporation indianapolis usd genentech usa inc south san francisco usd genentech inc south san francisco usd geneweave biosciences inc los gatos usd genia technologies inc mountain view usd hlr consumer health inc little falls usd hoffmannla roche inc little falls usd igen international inc pleasanton usd intermune inc south san francisco usd iquum inc marlborough usd kapa biosystems inc wilmington usd memory pharmaceuticals corp little falls usd roche carolina inc florence usd roche diabetes care inc indianapolis usd roche diagnostics corporation indianapolis usd roche diagnostics hematology inc westborough usd roche diagnostics operations inc indianapolis usd roche health solutions inc fishers usd roche holdings inc south san francisco usd roche laboratories inc little falls usd roche molecular systems inc pleasanton usd roche nimblegen inc madison usd roche palo alto llc south san francisco usd roche tcrc inc new york usd seragon pharmaceuticals inc south san francisco usd spring bioscience corp pleasanton usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch montevideo uyu venezuela productos roche sa caracas vef vietnam roche vietnam co ltd ho chi minh city usd share capital less local currency units roche finance report notes roche group consolidated financial statements roche group significant accounting policies consolidation policy subsidiaries companies including structured entities group control group controls entity group exposed rights variable returns involvement entity ability affect returns power entity companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control associates companies group exercises power exercise significant influence control accounted using equity method segment reporting purpose segment reporting groups corporate executive committee cec considered groups chief operating decision maker determination groups operating segments based organisation units information reported cec regular basis information provided used basis segment revenue profit disclosures reported note geographic analysis based location customers selected segment balance sheet information also routinely provided cec transfer prices operating segments set arms length basis operating assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt foreign currency translation annual financial statements presented swiss francs group companies use local currency functional currency certain group companies use currencies us dollar swiss franc euro functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity cases gains losses deferred comprehensive income upon consolidation assets liabilities group companies using functional currencies swiss francs translated swiss francs using yearend rates exchange income statement statement cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly comprehensive income roche finance report roche group notes roche group consolidated financial statements revenues sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates exclude value added taxes taxes directly linked sales revenues sale products recognised upon transfer customer significant risks rewards trade discounts cash discounts volume rebates recorded accrual basis consistent recognition related sales estimates expected sales returns chargebacks rebates including medicaid us similar rebates countries also deducted sales recorded accrued liabilities provisions deduction accounts receivable estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience circumstances level sales returns hence revenues reliably measured sales recognised right return expires generally upon prescription products patients revenues recorded earned services performed single transactions split separately identifiable components reflect substance transaction necessary conversely two transactions may considered together revenue recognition purposes commercial effect understood without reference series transactions whole cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered royalties alliance collaboration expenses including collaboration profitsharing arrangements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred research development internal research development activities expensed incurred following internal research costs incurred purpose gaining new scientific technical knowledge understanding internal development costs incurred application research findings knowledge plan develop new products commercial production development projects undertaken group subject technical regulatory uncertainties opinion management criteria capitalisation intangible assets met prior obtaining marketing approval regulatory authorities major markets postmarketing studies regulatory approval phase iv costs pharmaceuticals business generally involve safety surveillance ongoing technical support drug receives marketing approval sold may required regulatory authorities may undertaken safety commercial reasons costs postmarketing studies capitalised intangible assets opinion management generate separately identifiable incremental future economic benefits reliably measured acquired inprocess research development resources obtained inlicensing arrangements business combinations separate asset purchases capitalised intangible assets acquired asset must controlled group separately identifiable expected generate future economic benefits even uncertainty exists whether research development ultimately result marketable product consequently upfront milestone payments third parties pharmaceutical products compounds regulatory marketing approval recognised intangible assets assets acquired arrangements measured basis set intangible assets policy subsequent internal research development costs incurred post acquisition treated way internal research development costs research development embedded contracts strategic alliances group carefully assesses whether upfront milestone payments constitute funding research development work acquisition asset licensing milestone upfront receipts royalty income recognised accrual basis accordance substance respective licensing agreements collectability royalty amount reasonably assured royalties recognised revenue cash received certain group companies receive upfront milestone similar payments third parties relating sale licensing products technology revenue associated performance milestones recognised based achievement deliverables defined respective agreements upfront payments licence fees subsequent deliverables initially reported deferred income recognised income earned period development collaboration manufacturing obligation roche finance report notes roche group consolidated financial statements roche group employee benefits shortterm employee benefits include wages salaries social security contributions paid annual leave sick leave profit sharing bonuses nonmonetary benefits current employees costs recognised within operating results employee rendered associated service group recognises liability profit sharing bonuses contractually obliged past practice created constructive obligation longterm employee benefits include longservice sabbatical leave longservice benefits longterm disability benefits expected costs benefits accrued period employment changes carrying value longterm employee benefit liabilities recognised within operating results termination benefits payable employment terminated group normal retirement date whenever employee accepts voluntary redundancy exchange benefits termination costs recognised earlier group longer withdraw offer benefits group recognises related restructuring costs pensions postemployment benefits defined contribution plans group contributions recognised within operating results employee rendered associated service prepaid contributions recognised asset extent cash refund reduction future payments available defined benefit plans liability recognised balance sheet present value defined benefit obligation less fair value plan assets changes net defined benefit liability recognised occur follows recognised income statement current service costs charged appropriate income statement heading within operating results past service costs including curtailment gains losses recognised immediately general administration within operating results settlement gains losses recognised general administration within operating results net interest net defined benefit liability recognised financing costs recognised comprehensive income actuarial gains losses arising experience adjustments difference previous assumptions actually occurred changes actuarial assumptions return plan assets excluding amounts included net interest net defined benefit liability change limit recognition plan assets excluding amounts included net interest net defined benefit liability net interest net defined benefit liability comprised interest income plan assets interest cost defined benefit obligation interest effect limit recognition pension assets net interest calculated using discount rate used calculating defined benefit obligation applied net defined liability start period taking account changes contribution benefit payments pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan equity compensation plans fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded expense subsequent cash flows exercises vested awards recorded changes equity roche finance report roche group notes roche group consolidated financial statements property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful lives assets regularly reviewed necessary future depreciation charges accelerated repairs maintenance costs expensed incurred leases group lessee finance leases exist substantially risks rewards ownership transferred group finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt finance lease assets depreciated shorter lease term useful life interest element lease payment charged income lease term based effective interest rate method operating leases exist substantially risks rewards ownership transferred group payments made operating leases charged income straightline basis period lease group lessor certain assets mainly diagnostics instruments leased third parties finance operating lease arrangements finance lease assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method operating lease assets reported within property plant equipment lease income operating leases recognised lease term straightline basis business combinations business combinations accounted using acquisition method accounting date acquisition group initially recognises fair value identifiable assets acquired liabilities assumed noncontrolling interest acquired business consideration transferred measured fair value date acquisition group acquire ownership acquired business noncontrolling interests recorded either fair value proportion fair value acquired net assets attributable noncontrolling interest directly attributable acquisitionrelated costs expensed incurred within general administration expenses goodwill goodwill arises business combination excess consideration transferred acquire business underlying fair value net identified assets acquired goodwill amortised tested impairment least annually upon occurrence indication impairment roche finance report notes roche group consolidated financial statements roche group intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination initially recorded fair value available use intangible assets amortised straight line basis useful lives intangible assets reviewed impairment reporting date estimated useful life lower legal duration economic useful life estimated useful lives intangible assets regularly reviewed estimated useful lives major classes amortisable intangible assets follows product intangibles use years marketing intangibles use years technology intangibles use years impairment property plant equipment intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs disposal value use less carrying value carrying value reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm interest rate impairment loss arises useful life asset reviewed necessary future depreciation amortisation charge accelerated amount impairment loss subsequently decreases decrease related objectively event occurring impairment recognised previously recognised impairment loss reversed income statement impairment reversal impairment goodwill goodwill assessed impairment reporting date additionally tested annually impairment goodwill allocated cashgenerating units recoverable amount cashgenerating unit higher fair value less costs disposal value use less carrying value carrying value goodwill reduced recoverable amount reduction reported income statement impairment loss acquired business included within cash generating unit permanently ceases operate treated disposal business separately identifiable goodwill generated initial acquisition business factors made goodwill entirely unrelated continuing operations cashgenerating unit goodwill deemed disposed fully impaired impairment testing methodology described note inventories inventories stated lower cost net realisable value cost finished goods work process includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses accounts receivable accounts receivable carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances allowance doubtful accounts recorded objective evidence group able collect amounts due estimates based specific indicators ageing customer balances specific credit circumstances groups historical experience taking also account economic conditions expenses doubtful trade receivables recognised within marketing distribution expenses trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience roche finance report roche group notes roche group consolidated financial statements cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash equivalents readily convertible known amounts cash subject insignificant risk changes fair value maturity three months less date acquisition provisions contingencies provisions recognised legal constructive obligation incurred probably lead outflow resources reliably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise discounted time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available financial instruments financial instruments classified following categories disclosed note availableforsale nonderivative financial assets either designated classified financial asset category availableforsale assets initially recorded subsequently carried fair value changes fair value recorded comprehensive income except impairments interest foreign exchange components investment derecognised cumulative gains losses equity reclassified financial income expense availableforsale assets mainly comprised marketable securities fair value hedging instruments derivative financial instruments used manage exposures foreign currency interest rate equity market credit risks derivative financial instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments changes fair value recorded financial income expense fair value designated nonderivative financial instruments designated fair value profit loss initial recognition designated fair value instruments initially recorded subsequently carried fair value changes fair value recorded income statement designated fair value instruments mainly comprised contingent consideration liabilities changes fair value recorded general administration within operating results loans receivables nonderivative financial assets fixed determinable payments quoted active market loans receivables initially recorded fair value subsequently carried amortised cost using effective interest rate method less impairment losses loans receivables mainly comprised accounts receivable cash cash equivalents financial liabilities nonderivative financial liabilities financial liabilities initially recorded fair value subsequently carried amortised cost using effective interest rate method financial liabilities mainly comprised debt trade payables financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership financial asset transferred financial liability derecognised contractual obligations discharged cancelled expire roche finance report notes roche group consolidated financial statements roche group impairment financial assets financial assets individually assessed possible impairment reporting date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty available forsale equity securities market value original cost market value original cost sustained sixmonth period considered impaired financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial assets impairment charge amount currently carried comprehensive income difference original cost fair value impairment loss reversed reversal related objectively event occurring impairment loss recognised debt securities measured amortised cost availableforsale reversal recognised income equity securities held availableforsale reversal recognised directly comprehensive income hedge accounting group uses derivatives manage exposures foreign currency interest rate equity market credit risks instruments used may include interest rate swaps crosscurrency swaps forwards contracts options group generally limits use hedge accounting certain significant transactions qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income expense cash flow hedge hedge exposure variability cash flows attributable particular risk associated recognised asset liability highly probable forecast transaction could affect profit loss hedging instrument recorded fair value effective portion hedge included comprehensive income ineffective portion reported financial income expense hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial item cumulative changes fair value hedging instrument recorded comprehensive income included initial carrying value nonfinancial item date recognition cash flow hedges cumulative changes fair value hedging instrument recorded comprehensive income included financial income expense forecasted transaction affects net income fair value hedge hedge exposure changes fair value recognised asset liability unrecognised firm commitment identified portion asset liability firm commitment attributable particular risk could affect profit loss hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income expense debt debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted foreseeable future roche finance report roche group notes roche group consolidated financial statements deferred tax assets liabilities recognised temporary differences tax bases assets liabilities carrying values deferred tax assets recognised extent probable future taxable profit available unused tax losses utilised current deferred tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred taxes determined based currently enacted tax rates applicable tax jurisdiction group operates equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments held groups potential conversion obligations may arise groups equity compensation plans changes accounting policies group implemented various minor amendments existing standards interpretations material impact groups overall results financial position future new revised standards group currently assessing potential impacts various new revised standards interpretations mandatory january group yet applied based analysis date group anticipate material impact groups overall results financial position group also assessing new revised standards mandatory notably ifrs financial instruments ifrs revenues contracts customers ifrs leases roche finance report report roche management internal control financial reporting roche group report roche management internal control financial reporting report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reasonable assurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework version issued committee sponsoring organizations treadway commission coso based assessment management concluded system internal control financial reporting effective december statutory auditor kpmg ag audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa also issued report effectiveness groups system internal control financial reporting report set christoph franz alan hippe chairman board directors chief financial officer basel january roche finance report roche group report statutory auditor general meeting shareholders roche holding ltd basel report statutory auditor general meeting shareholders roche holding ltd basel report statutory auditor consolidated financial statements statutory auditor audited accompanying consolidated financial statements roche holding ltd comprise income statement statement comprehensive income balance sheet statement cash flows statement changes equity notes pages year ended december board directors responsibility board directors responsible preparation consolidated financial statements accordance international financial reporting standards ifrs requirements swiss law responsibility includes designing implementing maintaining internal control system relevant preparation consolidated financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion consolidated financial statements based audit conducted audit accordance swiss law swiss auditing standards international standards auditing standards require plan perform audit obtain reasonable assurance whether consolidated financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures consolidated financial statements procedures selected depend auditors judgement including assessment risks material misstatement consolidated financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation consolidated financial statements order design audit procedures appropriate circumstances audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation consolidated financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion consolidated financial statements year ended december give true fair view financial position results operations cash flows accordance international financial reporting standards ifrs comply swiss law report legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation consolidated financial statements according instructions board directors recommend consolidated financial statements submitted approved kpmg ag ian starkey marc ziegler licensed audit expert auditor charge licensed audit expert basel january roche finance report report independent auditor internal control financial reporting board directors roche holding ltd basel roche group report independent auditor internal control financial reporting board directors roche holding ltd basel report independent auditor internal control financial reporting examined roche groups system internal control financial reporting december based criteria established internal control integrated framework version issued committee sponsoring organizations treadway commission coso board directors management roche holding ltd responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying report roche management internal control financial reporting responsibility express opinion companys internal control financial reporting based examination entitys internal control financial reporting process effected entitys board directors management personnel designed provide reasonable assurance regarding reliability financial statements prepared accordance international financial reporting standards ifrs includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets entity provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance applicable financial reporting framework provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition entitys assets could material effect entitys financial statements conducted examination accordance international standard assurance engagements isae standard requires plan perform examination obtain reasonable assurance whether effective internal control financial reporting maintained material respects examination included obtaining understanding internal control financial reporting testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe examination provides reasonable basis opinion inherent limitations internal control financial reporting including possibility management override controls misstatements due error fraud may occur detected also projections evaluation internal control financial reporting future periods subject risk internal control may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion roche group maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework version issued committee sponsoring organizations treadway commission coso also audited accordance swiss auditing standards international standards auditing consolidated financial statements roche holding ltd year ended december report dated january expressed unqualified opinion consolidated financial statements kpmg ag ian starkey marc ziegler licensed audit expert auditor charge licensed audit expert basel january roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied retrospectively dividend proposed board directors roche finance report multiyear overview supplementary information roche group multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied retrospectively dividend proposed board directors roche finance report roche group multiyear overview supplementary information sales division millions chf pharmaceuticals diagnostics total sales geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics corporate total additions property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report multiyear overview supplementary information roche group supplementary core results eps information groups basic diluted earnings per share given note annual financial statements allow transparent assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core results concept used internal management business based ifrs results following adjustments global restructuring plans see note excluded amortisation impairment intangible assets see note impairment goodwill see note excluded acquisition accounting onetime impacts alliance arrangements business combinations see financial review excluded discontinued operations currently none would excluded legal environmental expenses see financial review excluded global issues outside healthcare sector beyond groups control currently none would excluded material onetime treasury items major debt restructurings see note excluded pension plan settlements see note excluded tax benefit recorded ifrs respect equity compensation plans ecps varies according price underlying equity replaced normalised tax benefit ifrs expense multiplied applicable tax rate see note core results concept described october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm groups ifrs results including divisional breakdown reconciled core results tables calculation core eps also given tables additional commentary adjustment items given financial review roche finance report roche group multiyear overview supplementary information core results reconciliation millions chf alliances normali global intangibles business legal major debt pension sation restruc amorti intangibles combi environ restruc plan ecp tax ifrs turing sation impairment nations mental turing settlements benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results reconciliation millions chf alliances normali global intangibles business legal major debt sation restruc amorti intangibles combi environ restruc ecp tax ifrs turing sation impairment nations mental turing benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests roche finance report multiyear overview supplementary information roche group divisional core results reconciliation millions chf alliances global intangibles business legal pension restruc amorti intangibles combi environ plan ifrs turing sation impairment nations mental settlements core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit divisional core results reconciliation millions chf alliances global intangibles business legal restruc amorti intangibles combi environ ifrs turing sation impairment nations mental core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary information core eps basic core net income attributable roche shareholders chf millions weighted average number shares nonvoting equity securities issue millions core earnings per share basic chf core eps diluted core net income attributable roche shareholders chf millions increase noncontrolling interests share core net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions core earnings per share diluted chf roche finance report multiyear overview supplementary information roche group supplementary operating free cash flow information divisional operating free cash flow information millions chf pharmaceuticals diagnostics corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets total adjustments add back expenses equitysettled equity compensation plans net income expense provisions net gain loss disposals noncash working capital items deduct utilisation provisions proceeds disposals total operating profit cash adjustments ebitda core operating profit depreciation impairment property plant equipment core basis ebitda margin sales roche finance report roche group multiyear overview supplementary information supplementary balance sheet information net operating assets balance sheet reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury roche group property plant equipment goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets net operating assets balance sheet reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury roche group property plant equipment goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets disclosed note goodwill intangible assets pharmaceuticals diagnostics divisions deferred tax net assets group december restated following finalisation valuation net assets acquired related intermune dutalys bina acquisitions reconciliation previously published balance sheet provided note roche finance report multiyear overview supplementary information roche group nongaap measures financial information included financial review includes certain nongaap measures accounting measures defined ifrs particular core results net working capital net operating assets free cash flow constant exchange rates nongaap measures used instead considered alternatives groups consolidated financial results based ifrs nongaap measures may comparable similarly titled measures disclosed companies core results core results allow assessment groups actual results defined ifrs underlying performance business core results concept explained net working capital net working capital used assess groups efficiency utilising assets shortterm liquidity net trade working capital calculated trade receivables inventories minus trade payables net working capital calculated net trade working capital adjusted receivables payables net operating assets net operating assets allow assessment groups operating performance business independently financing tax activities net operating assets calculated property plant equipment goodwill intangible assets net working capital longterm net operating assets minus provisions free cash flow free cash flow used assess groups ability generate cash required conduct maintain operations operating free cash flow calculated based ifrs operating profit adjusted certain cash items movements net working capital capital expenditures investments property plant equipment intangible assets free cash flow calculated operating free cash flow adjusted treasury activities taxes paid dividends paid constant exchange rates certain percentage changes financial review calculated using constant exchange rates cer allow assessment groups financial performance effects exchange rate fluctuations eliminated percentage changes constant exchange rates calculated using simulations reconsolidating current reported period prior period numbers constant currency exchange rates equalling average exchange rates prior year example cer change line item equivalent calculated using average exchange rate year ended december line item line item subsequently calculating change percent respect two recalculated numbers roche finance report roche group roche securities roche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr sp index rebased eight roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july information tables restated change ratio adrs effective january change ratio adrs effective january change ratio adrs effective february roche finance report roche securities roche group number shares nonvoting equity securities number shares nominal value chf number nonvoting equity securities genussscheine nominal value total number shares nonvoting equity securities genussscheine held total issue data per share nonvoting equity security chf earnings basic earnings diluted core earnings basic core earnings diluted equity attributable roche shareholders dividend c stock price share b opening high low yearend stock price nonvoting equity security genussschein b opening high low yearend market capitalisation millions chf yearend key ratios yearend dividend yield shares dividend yield nonvoting equity securities genussscheine priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed six swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors ticker symbols share nonvoting equity security american depositary receipt adr six swiss exchange ro rog bloomberg ro sw rog vx rhhby us reuters ros rogvx rhhbypk roche finance report roche holding ltd basel financial statements notes financial statements summary significant accounting policies ignificant shareholders hareholders equity f ulltime equivalents contingent liabilities board executive shareholdings appropriation available earnings report statutory auditor general meeting shareholders roche holding ltd basel roche finance report financial statements roche holding ltd basel financial statements balance sheet millions chf december december current assets cash cash equivalents marketable securities accounts receivable group companies shortterm loans group companies current receivables total current assets noncurrent assets longterm loans group companies investments total noncurrent assets total assets shortterm liabilities accounts payable group companies shortterm interestbearing liabilities group companies shortterm liabilities shortterm provisions total shortterm liabilities longterm liabilities provisions total longterm liabilities total liabilities shareholders equity share capital nonvoting equity securities genussscheine pm pm legal retained earnings general legal retained earnings voluntary reserves retained earnings free reserve special reserve available earnings balance brought forward previous year net income year equity instruments total shareholders equity total shareholders equity liabilities presentation balance sheet december adjusted following changes new law accounting financial reporting contained nd title swiss code obligations co adopted january pm pro memoria nonvoting equity securities nominal value roche finance report roche holding ltd basel financial statements income statement millions chf year ended december income income investments dividend income financial income interest income loans group companies income marketable securities guarantee fee income group companies income total income expenses administration expenses expenses financial expenses direct taxes total expenses net income presentation income statement year ended december adjusted following changes new law accounting financial reporting contained nd title swiss code obligations co adopted january roche finance report notes financial statements roche holding ltd basel notes financial statements summary significant accounting policies basis preparation financial statements roche holding ltd basel company prepared accordance provisions swiss law accounting financial reporting nd title swiss code obligations prescribed law significant accounting principles applied described changes new law accounting financial reporting contained nd title swiss code obligations co adopted january comparative financial information adjusted company prepared consolidated financial statements accordance recognised accounting standard international financial reporting standards accordance co company decided forgo presenting additional information audit fees notes well cash flow statement valuation methods translation foreign currencies marketable securities reported lower cost market value financial assets including investments reported cost less appropriate writedowns equity instruments recognised cost deducted equity time purchase equity instruments sold gain loss recognised income statement assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except investments translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred investments major direct indirect investments company listed note roche group annual financial statements ownership interests equal voting rights taxes direct taxes include corporate income capital taxes shareholders equity share capital previous year share capital amounts chf million share capital consists bearer shares nominal value chf included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value share capital participation certificates roche finance report roche holding ltd basel notes financial statements equity instruments company purchase roche shares company sold roche shares roche shares average sales price chf per share chf per share net gain chf million net gain chf million dividend income amounted chf million chf million december company held remaining roche shares roche shares cost chf million chf million deducted equity number equity instruments held company subsidiaries excluding foundations meets definitions requirements article b co within roche group annual financial statements entities mainly foundations included consolidation qualify subsidiaries article b co movement recognised amounts millions chf legal voluntary reserves retained earnings share retained free special available equity total capital earnings reserve reserve earnings instruments equity january net income dividends transactions equity instruments december net income dividends transactions equity instruments december net income dividends transactions equity instruments december movement recognised amounts equity adjusted following changes new law accounting financial reporting contained nd title swiss code obligations co adopted january contingent liabilities guarantees company issued guarantees certain bonds notes commercial paper credit facilities group companies nominal amount outstanding december chf billion chf billion described note roche group annual financial statements significant shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting march information available company roche finance report notes financial statements roche holding ltd basel controlling shareholders december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool december based information supplied group shares shares owned novartis ltd basel including affiliates thereof participation fulltime equivalents annual average number fulltime equivalents exceed ten people board executive shareholdings board directors directors mr andr hoffmann dr andreas oeri certain members founders families closely associated belong shareholder group pooled voting rights end group held shares issued shares detailed information group given note addition end year members board directors persons closely associated held shares nonvoting equity securities genussscheine shown table annual general meeting march dame deanne julius professor dr beatrice weder di mauro stand reelection mrs julie brown dr claudia sssmuth dyckerhoff nominated election new members board directors shareholdings members board directors nonvoting equity securities shares genussscheine c franz hoffmann p baschera j bell p bulcke julius rp lifton na na oeri b poussot na na schwan b c pr voser b weder di mauro total include shares held shareholder group pooled voting rights b equity compensation awards roche option plan ssars rsus roche performance share plan see c member corporate executive committee dr schwans shareholdings disclosed tables roche finance report roche holding ltd basel notes financial statements corporate executive committee members corporate executive committee persons closely associated held shares nonvoting equity securities shown table shareholdings members corporate executive committee nonvoting equity securities shares genussscheine schwan ayyoubi r diggelmann hippe ga keller b oday total equity compensation awards roche option plan ssars rsus roche performance share plan b close relatives dr keller held roche shares roche shares december members corporate executive committee held roche option plan awards rops stocksettled stock appreciation rights ssars shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages rops ssars awards held december year issue total schwan ayyoubi r diggelmann hippe ga keller oday total cec strike price chf expiry date mar mar mar mar feb feb feb december members corporate executive committee held restricted stock units rsus shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages rsu awards allocated individually remuneration committees discretion vested recipient three years thereafter nonvoting equity securities may remain blocked ten years rsu awards held december year issue total schwan ayyoubi r diggelmann hippe ga keller oday total cec roche finance report notes financial statements roche holding ltd basel december members corporate executive committee shown table held psp awards psp performance cycles terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages award result zero two nonvoting equity securities shares value adjustment depending upon achievement performance targets discretion board directors vesting nonvoting equity securities shares may remain blocked ten years end cycle performance targets achieved accordingly participants receive originally targeted nonvoting equity securities total target number awards outstanding performance cycles december shown table roche performance share plan awards held december psp psp schwan ayyoubi r diggelmann hippe ga keller oday total cec allocation date feb feb information relating number value rights options awards granted employees roche group members board directors corporate executive committee company disclosed note note roche group annual financial statements roche finance report roche holding ltd basel appropriation available earnings appropriation available earnings proposals annual general meeting chf available earnings balance brought forward previous year net profit year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year total appropriation available earnings carried forward account roche finance report report statutory auditor general meeting shareholders roche holding ltd basel roche holding ltd basel report statutory auditor general meeting shareholders roche holding ltd basel report statutory auditor financial statements statutory auditor audited accompanying financial statements roche holding ltd comprise balance sheet income statement notes pages year ended december board directors responsibility board directors responsible preparation financial statements accordance requirements swiss law companys articles incorporation responsibility includes designing implementing maintaining internal control system relevant preparation financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion financial statements based audit conducted audit accordance swiss law swiss auditing standards standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures financial statements procedures selected depend auditors judgement including assessment risks material misstatement financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation financial statements order design audit procedures appropriate circumstances purpose expressing opinion effectiveness entitys internal control system audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion financial statements year ended december comply swiss law companys articles incorporation report legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation financial statements according instructions board directors confirm proposed appropriation available earnings complies swiss law companys articles incorporation recommend financial statements submitted approved kpmg ag ian starkey marc ziegler licensed audit expert auditor charge licensed audit expert basel january roche finance report published cautionary statement regarding forwardlooking statements f hoffmannla roche ltd annual report contains certain forwardlooking statements group communications forwardlooking statements may identified words basel switzerland believes expects anticipates projects intends tel seeks estimates future similar expressions wwwrochecom discussion among things strategy goals plans intentions various factors may cause actual results differ order publications materially future reflected forwardlooking tel statements contained annual report among others fax pricing product initiatives competitors legislative email baselwebmasterrochecom regulatory developments economic conditions delay inability obtaining regulatory approvals bringing products media relations market fluctuations currency exchange rates general basel switzerland financial market conditions uncertainties discovery tel development marketing new products new uses existing email rochemediarelationsrochecom products including without limitation negative results clinical trials research projects unexpected side effects pipeline investor relations marketed products increased government pricing pressures basel switzerland interruptions production loss inability obtain tel adequate protection intellectual property rights litigation email investorrelationsrochecom loss key executives employees adverse publicity news coverage corporate sustainability committee tel statement regarding earnings per share growth profit email corporatesustainabilityrochecom forecast interpreted mean roches earnings earnings per share subsequent period next annual general meeting necessarily match exceed historical published earnings march earnings per share roche trademarks mentioned enjoy legal protection links thirdparty pages provided convenience express opinion content thirdparty pages expressly disclaim liability thirdparty information use roche finance report published german english case doubt differences interpretation english version shall prevail german text report consists actual annual report finance report contains annual report annual financial statements consolidated financial statements per articles incorporation sense management reporting printed nonchlorine bleached fsccertified paperfhoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche finance report finance report